								pa	rsit				
Ticker ABCL	Name AbCellera Biologics Inc.	Market_Cap	volume 1.5M	Beta Daily Volatility 2.13 2.5% - 7%	Latest Share Price \$2.49 - 01:30 PM EDT 06/10/2025	Insiders_Buying Yes - Moderate Purchase	Institutions_Buying		Sector Industry Healthcare Biotechnology	Drug_Name ABCL-001 ABCL-002	FDA-Approved_Drug/Drugs None	FDA_Fast_Track_Designations None	S Catalysts_Date Phase 1 Data Readout Q4 2025
	-	210M	350K	1.89 3% - 8%	\$5.12 - 01:30 PM EDT 06/10/2025	No No				EB-101 Pz-cel	None	Pz-cel Fast Track 2019	Phase 3 Data Readout Q2 2026
ABSI	Absci Corporation	450M	900K	2.45 3.5% - 9%	\$4.85 - 01:30 PM EDT 06/10/2025	No				ABSI-101	None	None	None
	Arbutus Biopharma Corporation ACADIA Pharmaceuticals Inc.	650M 2.8B	1.2M 1.1M	1.95 2.8% - 7.5% 1.34 2% - 6%	\$3.45 - 01:30 PM EDT 06/10/2025 \$15.20 - 01:30 PM EDT 06/10/2025					Imdusiran NUPLAZID DAYBUE	None NUPLAZID Apr 2016 DAYBUE Mar 2023	None NUPLAZID Fast Track 2014	Phase 2 Data Readout Q3 2026 Phase 3 Data Readout ACP-101 Q1 2026
ACET	Adicet Bio Inc.	150M	400K	1.78 3.2% - 8.5%	\$1.40 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare Biotechnology	ADI-001	None	None	Phase 1 Data Readout Q4 2025
ACLX	Arcellx Inc. Aclaris Therapeutics Inc.	1.9B 90M	500K 600K	1.65 2.5% - 7% 1.92 3% - 8%	\$55.30 - 01:30 PM EDT 06/10/2025 \$1.15 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			0,	Anito-cel ATI-1777	None None	Anito-cel Fast Track 2023 None	Phase 2 Data Readout Q3 2026 Phase 2b Data Readout Q2 2026
	Adaptimmune Therapeutics plc	200M	800K	2.01 3.5% - 9%	\$0.85 - 01:30 PM EDT 06/10/2025	No				Aficamten	None	Aficamten Fast Track 2022	Phase 3 Data Readout Q4 2026
	Adaptive Biotechnologies Corp. ADMA Biologics Inc.	650M 1.2B	700K 2.5M	1.87 2.8% - 7.5% 1.45 2% - 6%	\$3.60 - 01:30 PM EDT 06/10/2025 \$10.80 - 01:30 PM EDT 06/10/2025	No Yes - Large Purchase			Healthcare Biotechnology Healthcare Biotechnology	clonoSEQ ASCENIV BIVIGAM	clonoSEQ Sep 2018 ASCENIV Apr 2019 BIVIGAM Oct 2019	None None	New Indication Data Q3 2025 None
	Agenus Inc.	250M	1.8M	1.98 3.5% - 9%	\$0.65 - 01:30 PM EDT 06/10/2025	No No				Botensilimab	None None	None	Phase 2 Data Readout Q1 2026
		2.4B	600K	1.76 2.5% - 7%	\$43.50 - 01:30 PM EDT 06/10/2025				0,	PYRUKYND	PYRUKYND Feb 2022	PYRUKYND Fast Track 2020	Phase 3 Data Readout Q2 2026
	Aldeyra Therapeutics Inc. Alector Inc.	350M 450M	400K 500K	1.92 3% - 8% 1.67 2.8% - 7.5%	\$3.90 - 01:30 PM EDT 06/10/2025 \$5.10 - 01:30 PM EDT 06/10/2025	No No			Healthcare Biotechnology Healthcare Biotechnology	Reproxalap Latozinemab	None None	Reproxalap Fast Track 2019 Latozinemab Fast Track 2023	Phase 3 Data Readout Q4 2025 Phase 3 Data Readout Q3 2026
	Allogene Therapeutics Inc.	400M	900K	1.88 3.2% - 8.5%	\$2.70 - 01:30 PM EDT 06/10/2025				0,	Cema-cel	None	Cema-cel Fast Track 2022	Phase 2 Data Readout Q4 2026
	Alnylam Pharmaceuticals Inc. Amneal Pharmaceuticals Inc.	19.5B 2.1B	700K 1.3M	1.23 2% - 5.5% 1.45 2% - 6%	\$152.30 - 01:30 PM EDT 06/10/2025 \$6.95 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Pharmaceuticals	AMVUTTRA Givlaari Oxlumo Generic Drugs	AMVUTTRA Jun 2022 Givlaari Nov 2019 Oxlumo Nov 2020 N/A	N/A	Phase 3 Data Readout Vutrisiran Q1 2026 N/A
	Akero Therapeutics Inc.	1.8B	800K	1.78 2.8% - 7.5%	\$24.50 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology		None	EFX Fast Track 2020	Phase 3 Data Readout Q4 2026
	AnaptysBio Inc. Annovis Bio Inc.	650M 120M	300K 1.2M	1.65 2.5% - 7% 2.10 4% - 10%	\$24.80 - 01:30 PM EDT 06/10/2025 \$6.50 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Biotechnology	Rosnilimab Buntanetap	None None	None Buntanetap Fast Track 2023	Phase 2 Data Readout Q2 2026 Phase 3 Data Readout Q3 2026
APLS	Apellis Pharmaceuticals Inc.	4.8B	1.1M	1.54 2% - 6%	\$40.20 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare Biotechnology	SYOVRE Empaveli	SYOVRE Feb 2023 Empaveli May 2021	SYOVRE Fast Track 2022	Phase 3 Data Readout Q1 2026
ARDY	Arbutus Biopharma Corp. Ardelyx Inc.	450M 750M	600K 2.8M	1.92 3% - 8% 1.87 3.2% - 8.5%	\$3.10 - 01:30 PM EDT 06/10/2025 \$6.35 - 01:30 PM EDT 06/10/2025	No Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Biotechnology	ARCT-810 IBSRELA XPHOZAH	None IBSRELA Apr 2022 XPHOZAH Oct 2023	None IBSRELA Fast Track 2021	Phase 2 Data Readout Q4 2026 Phase 4 Data Readout Q3 2026
	argenx SE	12.5B	300K	1.12 1.8% - 5%	\$445.50 - 01:30 PM EDT 06/10/2025					VYVGART	VYVGART Jun 2021	VYVGART Fast Track 2020	Phase 3 Data Readout Efgartigimod Q2 2026
ARMP ARQT	Armata Pharmaceuticals Inc. Arcutis Biotherapeutics Inc.	75M 650M	50K 1.6M	1.92 3.5% - 9% 1.78 2.8% - 7.5%	\$2.80 - 01:30 PM EDT 06/10/2025 \$8.90 - 01:30 PM EDT 06/10/2025	No Yes - Moderate Purchase				AP-PA02 ZORYVE	None ZORYVE Jul 2022	None None	Phase 2 Data Readout Q3 2026 Phase 4 Data Readout Q2 2026
	Arvinas Inc.	1.4B	700K	1.87 2.5% - 7%	\$26.50 - 01:30 PM EDT 06/10/2025				0,	ARV-110	None	None	Phase 2 Data Readout Q4 2025
	Assembly Biosciences Inc.	90M	30K	1.65 3% - 8%	\$14.20 - 01:30 PM EDT 06/10/2025					ABI-4334	None	None	Phase 1b Data Readout Q3 2026
	Ascendis Pharma A/S Athira Pharma Inc.	4.8B 100M	300K 200K	1.45 2% - 6% 1.92 3.5% - 9%	\$135.40 - 01:30 PM EDT 06/10/2025 \$2.60 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology Healthcare Biotechnology	SKYTROFA YORVIPATH Fosgonimeton	SKYTROFA Aug 2021 YORVIPATH Aug 2024 None	SKYTROFA Fast Track 2020 None	Phase 3 Data Readout TransCon CNP Q1 2026 Phase 2/3 Data Readout Q4 2025
ATXS	Astria Therapeutics Inc.	350M	400K	1.76 2.8% - 7.5%	\$9.80 - 01:30 PM EDT 06/10/2025	No			0,	STAR-0215	None	STAR-0215 Fast Track 2023	Phase 1b Data Readout Q2 2026
	aTyr Pharma Inc. Aura Biosciences Inc.	150M 300M	250K 200K	1.87 3% - 8% 1.65 2.5% - 7%	\$1.95 - 01:30 PM EDT 06/10/2025 \$7.50 - 01:30 PM EDT 06/10/2025	No No				ATYR1923 Bel-sar	None None	None Bel-sar Fast Track 2022	Phase 2 Data Readout Q3 2026 Phase 3 Data Readout Q4 2026
AUPH	Aurinia Pharmaceuticals Inc.	900M	1.4M	1.54 2% - 6%	\$6.20 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare Biotechnology	LUPKYNIS	LUPKYNIS Jan 2021	LUPKYNIS Fast Track 2020	Phase 4 Data Readout Q3 2026
AVXL	Atea Pharmaceuticals Inc. Anavex Life Sciences Corp.	350M 450M	600K	1.78 2.8% - 7.5% 1.92 3.2% - 8.5%	\$4.10 - 01:30 PM EDT 06/10/2025 \$5.40 - 01:30 PM EDT 06/10/2025	No No			Healthcare Biotechnology Healthcare Biotechnology	Bemnifosbuvir Blarcamesine	None None	None Blarcamesine Fast Track 2021	Phase 3 Data Readout Q2 2026 Phase 3 Data Readout Q1 2026
AXSM	<u> </u>	3.8B	800K	1.65 2% - 6%	\$5.40 - 01:30 PM EDT 06/10/2025 \$85.60 - 01:30 PM EDT 06/10/2025					AUVELITY SUNOSI	AUVELITY Aug 2022 SUNOSI Jun 2019	AUVELITY Fast Track 2021	Phase 3 Data Readout Q1 2026 Phase 3 Data Readout AXS-12 Q4 2025
BBIO BCAX	BridgeBio Pharma Inc. Bicara Therapeutics Inc.	2.9B 700M	1.3M 400K	1.76 2.5% - 7% 1.54 2.8% - 7.5%	\$26.80 - 01:30 PM EDT 06/10/2025 \$18.50 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology Healthcare Biotechnology	Acoramidis Ficzeranib	None None	Acoramidis Fast Track 2023 None	Phase 3 Data Readout Q1 2026 Phase 2 Data Readout Q3 2026
	BioCryst Pharmaceuticals Inc.	700M 1.5B	2.5M	1.54 2.8% - 7.5% 1.87 2.5% - 7%	\$18.50 - 01:30 PM EDT 06/10/2025 \$7.90 - 01:30 PM EDT 06/10/2025	No Yes - Moderate Purchase				ORLADEYO ORLADEYO	ORLADEYO Dec 2020	ORLADEYO Fast Track 2020	Phase 2 Data Readout Q3 2026 Phase 3 Data Readout Avoralstat Q2 2026
	Beam Therapeutics Inc.	1.7B	900K	1.92 3% - 8%	\$24.30 - 01:30 PM EDT 06/10/2025				0,	BEAM-101	None SPINDAZA Doc 2016 LEOEMBL Jon 2023	BEAM-101 Fast Track 2022	Phase 1 Data Readout Q4 2025
BIIB	Biogen Inc. BioLineRx Ltd.	27.5B 150M	1.2M 500K	1.23 1.8% - 5% 1.65 3.2% - 8.5%	\$190.20 - 01:30 PM EDT 06/10/2025 \$0.70 - 01:30 PM EDT 06/10/2025	Ves - Large Purchase No	Stable Decrease		Healthcare Biotechnology Healthcare Biotechnology	SPINRAZA LEQEMBI APHEXDA	SPINRAZA Dec 2016 LEQEMBI Jan 2023 APHEXDA Sep 2023	LEQEMBI Fast Track 2022 APHEXDA Fast Track 2022	Phase 3 Data Readout Q1 2026 Commercial Expansion Q4 2025
	Biomea Fusion Inc.	250M	600K	2.01 3.5% - 9%	\$6.80 - 01:30 PM EDT 06/10/2025	No No				BMF-219	None	None	Phase 2 Data Readout Q3 2026
	BioMarin Pharmaceutical Inc. BioNTech SE	14.5B 22.8B	1.4M 700K	1.34 1.8% - 5% 1.45 2% - 6%	\$78.50 - 01:30 PM EDT 06/10/2025 \$95.20 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology Healthcare Biotechnology	VOXZOGO ROCTAVIAN COMIRNATY	VOXZOGO Nov 2021 ROCTAVIAN Jun 2023 COMIRNATY Aug 2021	VOXZOGO Fast Track 2020 COMIRNATY Fast Track 2020	Phase 3 Data Readout BMN 307 Q2 2026 Phase 3 Data Readout BNT324 Q1 2026
	Blueprint Medicines Corp.	3.5B	500K	1.54 2.5% - 7%	\$95.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare Biotechnology	AYVAKIT GAVRETO	AYVAKIT Jun 2020 GAVRETO Sep 2020	AYVAKIT Fast Track 2020	Phase 3 Data Readout BLU-222 Q4 2025
BTAI	BioXcel Therapeutics Inc. Candel Therapeutics Inc.	150M 120M	700K 1.2M	2.10 3.5% - 9% 2.10 3.5% - 9%	\$1.80 - 01:30 PM EDT 06/10/2025 \$5.80 - 01:30 PM EDT 06/10/2025	No No				BXCL501 CAN-2409	IGALMI Apr 2022 None	IGALMI Fast Track 2021 CAN-2409 Fast Track 2021	Phase 3 Data Readout BXCL501 Q3 2026 Phase 3 Data Readout Q4 2025
	<u> </u>	50M	150K	1.87 3% - 8%	\$2.10 - 01:30 PM EDT 06/10/2025	No				Namodenoson	None	None	Phase 3 Data Readout Q3 2026
CAPR CELC	Capricor Therapeutics Inc. Celcuity Inc.	150M 350M	400K 200K	1.92 3.2% - 8.5% 1.76 2.8% - 7.5%	\$5.40 - 01:30 PM EDT 06/10/2025 \$16.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Biotechnology	Deramiocel Gedatolisib	None None	Deramiocel Fast Track 2023 None	Phase 3 Data Readout Q2 2026 Phase 3 Data Readout Q4 2026
CELU	Celularity Inc.	80M	300K	1.76 2.8% - 7.5% 1.98 3.5% - 9%	\$2.90 - 01:30 PM EDT 06/10/2025	No				CYNK-001	None	None	Phase 1 Data Readout Q3 2026
CELZ	Creative Medical Technology Holdings Inc.		50K	2.01 4% - 10%	\$3.50 - 01:30 PM EDT 06/10/2025	No No			0,	CELZ-201	None	None	None
	Celldex Therapeutics Inc. Cullinan Oncology Inc.	1.8B 600M	600K 400K	1.65 2.5% - 7% 1.54 2.8% - 7.5%	\$38.50 - 01:30 PM EDT 06/10/2025 \$17.20 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology Healthcare Biotechnology	Barzolvolimab Zipalertinib	None None	Barzolvolimab Fast Track 2023 None	Phase 2 Data Readout Q1 2026 Phase 3 Data Readout Q4 2026
	CG Oncology Inc.	1.2B	500K	1.45 2.5% - 7%	\$32.40 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology	Cretostimogene	None	Cretostimogene Fast Track 2023	
	Cognition Therapeutics Inc. Coherus BioSciences Inc.	90M 150M	200K 1.5M	1.92 3.2% - 8.5% 2.01 3.5% - 9%	\$2.30 - 01:30 PM EDT 06/10/2025 \$1.60 - 01:30 PM EDT 06/10/2025	No No			Healthcare Biotechnology Healthcare Biotechnology	CT1812 UDENYCA	None UDENYCA Nov 2018	None UDENYCA Fast Track 2018	Phase 2 Data Readout Q3 2026 Commercial Expansion Q4 2025
СКРТ	<u> </u>	80M	600K	1.87 3% - 8%	\$2.20 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare Biotechnology	Cosibelimab	None	Cosibelimab Fast Track 2022	Phase 3 Data Readout Q1 2026
CLSD	Clearside Biomedical Inc. Cellectis S.A.	90M 200M	400K 150K	1.92 3.2% - 8.5% 1.76 2.8% - 7.5%	\$1.20 - 01:30 PM EDT 06/10/2025 \$2.50 - 01:30 PM EDT 06/10/2025	No No				CLS-AX UCART123	None None	None	Phase 2b Data Readout Q4 2025 Phase 1 Data Readout Q3 2026
	Compass Therapeutics Inc.	120M	300K	1.65 3% - 8%	\$1.40 - 01:30 PM EDT 06/10/2025	No			0,	CTX-009	None	None	Phase 2 Data Readout Q2 2026
CNTA	Centessa Pharmaceuticals plc Cogent Biosciences Inc.	800M 650M	400K 700K	1.54 2.5% - 7% 1.87 2.8% - 7.5%	\$9.80 - 01:30 PM EDT 06/10/2025 \$8.90 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Biotechnology	SerpinPC Bezuclastinib	None None	SerpinPC Fast Track 2023 None	Phase 2b Data Readout Q4 2025 Phase 3 Data Readout Q3 2026
	Coya Therapeutics Inc.	200M	150K	1.92 3.2% - 8.5%	\$7.20 - 01:30 PM EDT 06/10/2025	No				COYA 301	None	None	Phase 2 Data Readout Q4 2026
	<u> </u>	3.2B 2.6B	800K 1.2M	1.45 2% - 6% 1.34 2% - 6%	\$34.50 - 01:30 PM EDT 06/10/2025 \$25.90 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase Yes - Large Purchase				KORLYM FIRDAPSE AGAMREE	KORLYM Feb 2012 FIRDAPSE Nov 2018 AGAMREE Oct 2023	None FIRDAPSE Fast Track 2018	Phase 3 Data Readout Relacorilant Q1 2026 Phase 4 Data Readout Q3 2026
	Corbus Pharmaceuticals Holdings Inc.	450M	1.1M	1.76 2.8% - 7.5%	\$9.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase				CRB-701	None None	None	Phase 2 Data Readout Q4 2025
CRIS	Curis Inc.	80M	200K 500K	1.92 3.2% - 8.5% 1.65 2.5% - 7%	\$4.50 - 01:30 PM EDT 06/10/2025 \$5.60 - 01:30 PM EDT 06/10/2025	No			Healthcare Biotechnology	Emavusertib DEFENCATH	None DEFENCATH Oct 2023	None	Phase 2 Data Readout Q3 2026
CRMD	CorMedix Inc. Crinetics Pharmaceuticals Inc.	200M 2.5B	600K	1.54 2.5% - 7%	\$48.70 - 01:30 PM EDT 06/10/2025	No Yes - Large Purchase				Paltusotine	None	DEFENCATH Fast Track 2022 Paltusotine Fast Track 2023	Commercial Expansion Q4 2025 Phase 3 Data Readout Q1 2026
	<u> </u>	4.8B	1.9M	1.87 2.5% - 7%	\$58.40 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology	Casgevy	Casgevy Dec 2023	Casgevy Fast Track 2022	Phase 3 Data Readout CTX112 Q4 2025
	CytomX Therapeutics Inc. Cytokinetics Incorporated	150M 4.5B	700K	1.92 3.2% - 8.5% 1.76 2.5% - 7%	\$1.40 - 01:30 PM EDT 06/10/2025 \$55.80 - 01:30 PM EDT 06/10/2025	No Yes - Moderate Purchase				CX-904 Omecamtiv Mecarbil	None None	None Omecamtiv Fast Track 2020	Phase 1 Data Readout Q3 2026 Phase 3 Data Readout Aficamten Q1 2026
	<u> </u>	1.2B	600K	1.65 2.8% - 7.5%	\$14.50 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology	Tovorafenib	Ojemda Apr 2024	Ojemda Fast Track 2022	Phase 3 Data Readout Q4 2025
	Denali Therapeutics Inc. Dynavax Technologies Corporation	2.8B 1.4B	800K 1.3M	1.54 2.5% - 7% 1.45 2% - 6%	\$24.30 - 01:30 PM EDT 06/10/2025 \$11.20 - 01:30 PM EDT 06/10/2025					DNL310 HEPLISAV-B	None HEPLISAV-B Nov 2017	DNL310 Fast Track 2021 None	Phase 2 Data Readout Q2 2026 Commercial Expansion Q4 2025
EDIT	Editas Medicine Inc.	350M	1.5M	1.92 3% - 8%	\$5.10 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare Biotechnology	EDIT-301	None	EDIT-301 Fast Track 2022	Phase 1/2 Data Readout Q4 2025
	Elanco Animal Health Incorporated Elevation Oncology Inc.	6.8B 80M	2.1M 400K	1.34 1.8% - 5% 2.01 3.5% - 9%	\$14.50 - 01:30 PM EDT 06/10/2025 \$0.85 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase				Zenrelia Credelio Seribantumab	Multiple Products None	None None	Commercial Expansion Q4 2025 Phase 2 Data Readout Q3 2026
	Enliven Therapeutics Inc.	1.1B	300K	1.54 2.5% - 7%	\$24.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Clinical	Healthcare Biotechnology	ELVN-001	None	None	Phase 1 Data Readout Q4 2025
ENTA EOLS	Enanta Pharmaceuticals Inc. Evolus Inc.	300M 650M	200K 600K	1.76 2.8% - 7.5% 1.45 2% - 6%	\$12.50 - 01:30 PM EDT 06/10/2025 \$12.30 - 01:30 PM EDT 06/10/2025				0.	EDP-938 Jeuveau	None Jeuveau Feb 2019	None None	Phase 2 Data Readout Q2 2026 Commercial Expansion Q4 2025
EPIX	ESSA Pharma Inc.	200M	150K	1.92 3.2% - 8.5%	\$6.80 - 01:30 PM EDT 06/10/2025	No				Masofaniten	None None	None	Phase 2 Data Readout Q3 2026
ERAS ETNB	Erasca Inc. 89bio Inc.	650M 600M	700K 500K	1.65 2.5% - 7% 1.87 2.8% - 7.5%	\$3.10 - 01:30 PM EDT 06/10/2025 \$8.50 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Biotechnology	Naporafenib Pegozafermin	None None	None Pegozafermin Fast Track 2022	Phase 3 Data Readout Q4 2025 Phase 3 Data Readout Q2 2026
EXAI	Exscientia plc	650M	400K	1.54 2.5% - 7%	\$5.20 - 01:30 PM EDT 06/10/2025	No			Healthcare Biotechnology	EXS-21546	None	None	Phase 1 Data Readout Q3 2026
EXEL EYEN		6.2B 80M	1.8M 600K	1.34 1.8% - 5% 2.01 3.5% - 9%	\$26.80 - 01:30 PM EDT 06/10/2025 \$0.90 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase				Cabometyx Cometriq Mydcombi	Cabometyx Apr 2016 Cometriq Nov 2012 Mydcombi May 2023	Cabometyx Fast Track 2015 Mydcombi Fast Track 2022	Phase 3 Data Readout Zanzalintinib Q1 2026 Commercial Expansion Q4 2025
	EyePoint Pharmaceuticals Inc.	450M	500K	1.76 2.8% - 7.5%	\$9.50 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase				YUTIQ	YUTIQ Oct 2018	YUTIQ Fast Track 2018	Phase 3 Data Readout EYP-1901 Q4 2025
	·	650M 90M	400K 1.2M	1.87 3% - 8% 2.10 3.5% - 9%	\$14.20 - 01:30 PM EDT 06/10/2025 \$0.95 - 01:30 PM EDT 06/10/2025	No No			Healthcare Biotechnology Healthcare Biotechnology	4D-150 Pamrevlumab	None None	4D-150 Fast Track 2023 None	Phase 2 Data Readout Q3 2026 Phase 3 Data Readout Q4 2025
FOLD	Amicus Therapeutics Inc.	2.8B	1.2M 1.4M	2.10 3.5% - 9% 1.45 2% - 6%	\$0.95 - 01:30 PM EDT 06/10/2025 \$10.20 - 01:30 PM EDT 06/10/2025					Galafold Pombiliti	Galafold Aug 2018 Pombiliti Sep 2023	None Galafold Fast Track 2017	Phase 3 Data Readout Q4 2025 Phase 4 Data Readout Q3 2026
		2.2B	900K	1.34 1.8% - 5%	\$24.50 - 01:30 PM EDT 06/10/2025 \$6.80 - 01:30 PM EDT 06/10/2025				Healthcare CRO	N/A	N/A None	N/A Losmanimod Fast Track 2021	N/A Phase 3 Data Readout O4 2025
	Fulcrum Therapeutics Inc. Geron Corporation	350M 2.1B	600K 2.5M	1.92 3% - 8% 1.76 2.8% - 7.5%	\$6.80 - 01:30 PM EDT 06/10/2025 \$4.50 - 01:30 PM EDT 06/10/2025	No Yes - Large Purchase				Losmapimod Rytelo	None Rytelo Jun 2024	Losmapimod Fast Track 2021 Rytelo Fast Track 2023	Phase 3 Data Readout Q4 2025 Commercial Expansion Q4 2025
GILD	Gilead Sciences Inc.	138.5B	6.2M	1.34 1.8% - 5%	\$110.75 - 01:30 PM EDT 06/10/2025					Biktarvy Yescarta Trodelvy	Biktarvy Feb 2018 Yescarta Oct 2017 Trodelvy Apr 2020	Biktarvy Fast Track 2017	Phase 3 Data Readout GS-1427 Q1 2026
GLPG GLSI	Galapagos NV Greenwich LifeSciences Inc.	1.2B 350M	200K 150K	1.45 2% - 6% 1.92 3.2% - 8.5%	\$27.50 - 01:30 PM EDT 06/10/2025 \$12.22 - 01:30 PM EDT 06/10/2025					JYSELECA GP2	JYSELECA (EU Approved 2020) None	None	Phase 3 Data Readout GLPG3667 Q4 2025 Phase 3 Data Readout Q3 2026
	GlycoMimetics Inc.	80M	600K	2.01 3.5% - 9%	\$0.45 - 01:30 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare Biotechnology	Uproleselan	None	Uproleselan Fast Track 2017	Phase 3 Data Readout Q4 2025
	Genmab A/S Gyre Therapeutics Inc.	7.8B 200M	500K 300K	1.23 1.8% - 5% 1.76 3% - 8%	\$28.50 - 01:30 PM EDT 06/10/2025 \$12.80 - 01:30 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology Healthcare Biotechnology	Darzalex Epcoritamab ETUARY	Darzalex Jun 2016 Epcoritamab May 2023 None	Darzalex Fast Track 2015 None	Phase 3 Data Readout GEN1046 Q2 2026 Phase 3 Data Readout Q4 2025
HALO	Halozyme Therapeutics Inc.	7.2B	1.1M	1.34 1.8% - 5%	\$50.20 - 01:30 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Commercial	Healthcare Biotechnology	ENHANZE Technology	Multiple ENHANZE-based drugs	None	Commercial Expansion Q4 2025
	·	80M 2.5B	400K 600K	2.01 3.5% - 9% 1.45 2% - 6%	\$0.65 - 01:30 PM EDT 06/10/2025 \$38.50 - 01:30 PM EDT 06/10/2025	No Yes - Moderate Purchase				HB-200 WAKIX	None WAKIX Aug 2019	None WAKIX Fast Track 2018	Phase 2 Data Readout Q3 2026 Phase 3 Data Readout Pitolisant Q2 2026
ICPT	Intercept Pharmaceuticals Inc.	1.5B	800K	1.76 2.5% - 7%	\$19.00 - 01:30 PM EDT 06/10/2025	No	Stable	Commercial	Healthcare Biotechnology	Ocaliva	Ocaliva May 2016	Ocaliva Fast Track 2015	Phase 4 Data Readout Q4 2025
IDYA IMCR		2.8B 2.1B	500K 600K	1.54 2.5% - 7% 1.87 2.8% - 7.5%	\$38.20 - 01:30 PM EDT 06/10/2025 \$40.50 - 01:30 PM EDT 06/10/2025				Healthcare Biotechnology Healthcare Biotechnology	Darovasertib KIMMTRAK	None KIMMTRAK Jan 2022	Darovasertib Fast Track 2022 KIMMTRAK Fast Track 2021	Phase 3 Data Readout Q1 2026 Phase 3 Data Readout IMC-M113V Q2 2026
IMMX	<u> </u>	2.1B 80M	300K	2.10 3.5% - 9%	\$40.50 - 01:30 PM EDT 06/10/2025 \$2.10 - 01:30 PM EDT 06/10/2025	No				IMX-110	None None	IMX-110 Fast Track 2022	Phase 2 Data Readout IMC-M113V Q2 2026 Phase 2 Data Readout Q3 2026
	Immunome Inc.	600M	500K	1.76 2.8% - 7.5%	\$15.80 - 01:30 PM EDT 06/10/2025					IMM-101	None	None Rateolimah Fact Track 2022	Phase 1 Data Readout Q4 2025
INBX	Immunovant Inc. Inhibrx Inc.	3.5B 450M	700K 400K	1.65 2.5% - 7% 1.92 3% - 8%	\$30.20 - 01:30 PM EDT 06/10/2025 \$14.50 - 01:30 PM EDT 06/10/2025	-				Batoclimab INBRX-101	None None	Batoclimab Fast Track 2023 None	Phase 3 Data Readout Q1 2026 Phase 2 Data Readout Q4 2025
INCY	Incyte Corporation	13.8B	1.8M	1.45 1.8% - 5%	\$65.20 - 01:30 PM EDT 06/10/2025			Commercial	Healthcare Biotechnology	Jakafi Opzelura	Jakafi Feb 2011 Opzelura Sep 2021	Jakafi Fast Track 2010	Phase 3 Data Readout INCB54707 Q2 2026
INSM	Insmed Incorporated Innoviva Inc.	10.2B 2.1B	1.5M 600K	1.54 2% - 6% 1.34 1.8% - 5%	\$68.50 - 01:30 PM EDT 06/10/2025 \$18.50 - 01:30 PM EDT 06/10/2025					Arikayce Relvar Breo Ellipta	Arikayce Sep 2018 Relvar Breo Ellipta May 2013	Arikayce Fast Track 2018 None	Phase 3 Data Readout TPIP Q1 2026 Commercial Expansion Q4 2025
INZY	Inozyme Pharma Inc.	200M	300K	1.87 3% - 8%	\$5.20 - 01:30 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	INZ-701	None	INZ-701 Fast Track 2022	Phase 3 Data Readout Q4 2025
IOVA	·	2.4B 7.5B	1.9M 700K	1.76 2.8% - 7.5% 1.45 2% - 6%	\$10.80 - 01:30 PM EDT 06/10/2025 \$78.50 - 01:30 PM EDT 06/10/2025					Amtagvi Lumateperone	Amtagvi Feb 2024 Caplyta Dec 2019	Amtagvi Fast Track 2023 Caplyta Fast Track 2018	Phase 3 Data Readout LN-145 Q2 2026 Phase 3 Data Readout ITI-214 Q1 2026
1101	Invivyd Inc.	150M	500K	2.01 3.5% - 9%		No				INV104	None	INV104 Fast Track 2023	Phase 3 Data Readout Q3 2026
IVVD					4	Yes - Moderate Purchase	Increase	Clinical	Healthcare Biotechnology	JANX007	None	None	Phase 1 Data Readout Q4 2025
IVVD JANX	Janux Therapeutics Inc.	1.8B 6.8B	600K	1.65 2.5% - 7% 1.34 1.8% - 5%	\$45.20 - 01:30 PM EDT 06/10/2025 \$110.20 - 01:55 PM EDT 06/10/2025		Stable	Commoroial	Healthcare Riotochasta	Xvrem Xvwav Enidialar	Xvrem Jul 2002 Xvwav Jul 2020 Epidiolog Jun 2010	Xyway Fast Track 2010	Phase 3 Data Readout Suyocaltonide O4 2005
IVVD JANX	· · · · · · · · · · · · · · · · · · ·	1.8B 6.8B 150M	600K 600K 400K	1.65 2.5% - 7% 1.34 1.8% - 5% 1.92 3.2% - 8.5%	\$45.20 - 01:30 PM EDT 06/10/2025 \$110.20 - 01:55 PM EDT 06/10/2025 \$2.80 - 01:55 PM EDT 06/10/2025	Yes - Large Purchase				Xyrem Xywav Epidiolex Briquilimab	Xyrem Jul 2002 Xywav Jul 2020 Epidiolex Jun 2018 None	Xywav Fast Track 2019 None	Phase 3 Data Readout Suvecaltamide Q4 2025 Phase 2 Data Readout Q3 2026
JANX JAZZ JSPR KALV	Jazz Pharmaceuticals plc Jasper Therapeutics Inc. KalVista Pharmaceuticals Inc.	6.8B	600K	1.34 1.8% - 5% 1.92 3.2% - 8.5%	\$110.20 - 01:55 PM EDT 06/10/2025 \$2.80 - 01:55 PM EDT 06/10/2025	Yes - Large Purchase No No	Decrease Stable	Clinical Clinical	Healthcare Biotechnology Healthcare Biotechnology		· ·	-	

COD Kadiak Cajanasa k		00014	COOK	0.01 0.50/ 00/	\$0.00 04.55 DM EDT 00/40/0005	Na	Decrees	Clinical	Haalthaana Diatashaalaan	Tayaaaiyaab	Nene	News	Dhasa O Data Daadaut O4 0005
KROS Keros Therapeutics		200M 1.8B		2.01 3.5% - 9% 1.54 2.5% - 7%	\$3.20 - 01:55 PM EDT 06/10/2025 \$48.50 - 01:55 PM EDT 06/10/2025		Decrease		Healthcare Biotechnology Healthcare Biotechnology	Tarcocimab Elritercept	None	None	Phase 3 Data Readout Q4 2025 Phase 2 Data Readout Q1 2026
KURA Kura Oncology Inc.		1.2B		1.87 2.8% - 7.5%	\$20.80 - 01:55 PM EDT 06/10/2025		Stable		Healthcare Biotechnology	Ziftomenib	None	Ziftomenib Fast Track 2023	Phase 2 Data Readout Q4 2025
KTTA Krystal Biotech Inc.		5.2B	300K	1.45 2% - 6%	\$180.50 - 01:55 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	Vyjuvek	Vyjuvek May 2023	Vyjuvek Fast Track 2022	Phase 3 Data Readout KB707 Q2 2026
KYMR Kymera Therapeuti	tics Inc.	2.5B	500K	1.65 2.5% - 7%	\$38.20 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare Biotechnology	KT-474	None	None	Phase 2 Data Readout Q1 2026
Legend Biotech Co	orporation	8.5B	1.1M	1.54 2% - 6%	\$46.50 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare Biotechnology	Carvykti	Carvykti Feb 2022	Carvykti Fast Track 2021	Phase 3 Data Readout LB-100 Q3 2026
Lenz Therapeutics	Inc.	350M	200K	1.92 3.2% - 8.5%	\$15.80 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	LNZ100	None	LNZ100 Fast Track 2023	Phase 3 Data Readout Q4 2025
.GND Ligand Pharmaceur	uticals Inc.	1.8B	300K	1.45 2% - 6%	\$98.50 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare Biotechnology	Captisol Technology	Multiple Captisol-based drugs	None	Commercial Expansion Q4 2025
.QDA Liquidia Corporatio		650M		1.87 2.8% - 7.5%	\$12.20 - 01:55 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	Yutrepia	Yutrepia Nov 2024	Yutrepia Fast Track 2022	Commercial Expansion Q4 2025
RMR Larimar Therapeution		300M	400K	1.92 3.2% - 8.5%	·		Stable		Healthcare Biotechnology	Nomlabofusp	None	Nomlabofusp Fast Track 2023	Phase 2 Data Readout Q2 2026
XRX Lexicon Pharmace		350M		2.01 3.5% - 9%	·		Decrease		Healthcare Biotechnology	Inpefa	Inpefa May 2023	Inpefa Fast Track 2022	Phase 3 Data Readout LX9211 Q3 2026
YEL Lyell Immunopharm IDGL Madrigal Pharmace		200M 5.5B		1.76 3% - 8% 1.65 2.5% - 7%	\$2.80 - 01:55 PM EDT 06/10/2025 \$280.50 - 01:55 PM EDT 06/10/2025		Decrease Increase		Healthcare Biotechnology Healthcare Biotechnology	LYL797 Rezdiffra	None Rezdiffra Mar 2024	LYL797 Fast Track 2023 Rezdiffra Fast Track 2022	Phase 1 Data Readout Q4 2025 Commercial Expansion Q4 2025
MESO Mesoblast Limited		1.2B		1.87 2.8% - 7.5%	\$7.50 - 01:55 PM EDT 06/10/2025	-	Stable		Healthcare Biotechnology	Remestemcel-L	None	Remestemcel-L Fast Track 2019	·
IGNX MacroGenics Inc.		200M		2.01 3.5% - 9%			Decrease		Healthcare Biotechnology	Vobramitamab	None	None	Phase 2 Data Readout Q3 2026
MGTX MeiraGTx Holdings	s plc	350M	300K	1.76 2.8% - 7.5%	\$5.20 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	AAV-GAD	None	None	Phase 2 Data Readout Q4 2025
MGX Metagenomi Inc.		150M	400K	1.92 3.2% - 8.5%	\$4.80 - 01:55 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare Biotechnology	MGX-001	None	None	Phase 1 Data Readout Q3 2026
MIRM Mirum Pharmaceut	ticals Inc.	1.5B	500K	1.65 2.5% - 7%	\$38.20 - 01:55 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare Biotechnology	Livmarli	Livmarli Nov 2020	Livmarli Fast Track 2020	Phase 3 Data Readout Volixibat Q1 2026
MLYS Mineralys Therapeu	utics Inc.	450M	300K	1.87 2.8% - 7.5%	\$13.50 - 01:55 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	Lorundrostat	None	None	Phase 3 Data Readout Q4 2025
MannKind Corpora		1.4B		1.76 2.8% - 7.5%	·	Yes - Moderate Purchase	Increase		Healthcare Biotechnology	Afrezza	Afrezza Jun 2014	Afrezza Fast Track 2013	Commercial Expansion Q4 2025
MNMD Mind Medicine (Mir	·	600M		2.01 3.5% - 9%	, , , , , , , , , , , , , , , , , , , ,		Increase		Healthcare Biotechnology	MM-120	None	MM-120 Fast Track 2022	Phase 3 Data Readout Q3 2026
MREO Mereo BioPharma (MRNS Marinus Pharmace)		600M 80M		1.76 2.8% - 7.5% 2.01 3.5% - 9%	\$4.50 - 01:58 PM EDT 06/10/2025 \$1.40 - 01:58 PM EDT 06/10/2025				Healthcare Biotechnology		None Ztalmy Mar 2022	Setrusumab Fast Track 2022 Ganaxolone Fast Track 2021	Phase 3 Data Readout Q4 2025 Phase 3 Data Readout Q3 2026
MRSN Mersana Therapeut		150M		1.92 3.2% - 8.5%	·		Decrease Stable		Healthcare Biotechnology Healthcare Biotechnology	XMT-1660	None	None	Phase 1 Data Readout Q4 2025
MRUS Merus N.V.	ilios irio.	2.5B	500K	1.65 2.5% - 7%	\$55.80 - 01:58 PM EDT 06/10/2025				Healthcare Biotechnology	Zenocutuzumab	None		Phase 2 Data Readout Q1 2026
ITEM Molecular Template	tes Inc.	80M		2.10 3.5% - 9%	\$1.20 - 01:58 PM EDT 06/10/2025		Decrease		Healthcare Biotechnology		None	None	Phase 1 Data Readout Q3 2026
IAMS NewAmsterdam Ph		1.8B		1.54 2.5% - 7%	·		Increase		Healthcare Biotechnology		None	None	Phase 3 Data Readout Q4 2025
Nautilus Biotechno	ology Inc.	200M	200K	1.76 2.8% - 7.5%	\$2.80 - 01:58 PM EDT 06/10/2025	No	Stable	Pre-Clinical	Healthcare Biotechnology	N/A	None	None	None
Nanobiotix S.A.		350M	150K	1.87 3% - 8%	\$6.50 - 01:58 PM EDT 06/10/2025	No	Decrease	Clinical	Healthcare Biotechnology	NBTXR3	None	NBTXR3 Fast Track 2022	Phase 3 Data Readout Q2 2026
Nurix Therapeutics		1.2B	600K	1.92 3.2% - 8.5%	<u> </u>				Healthcare Biotechnology	NX-5948	None	None	Phase 1 Data Readout Q4 2025
ITLA Intellia Therapeutic	es Inc.	2.1B		1.76 2.8% - 7.5%	\$22.50 - 01:58 PM EDT 06/10/2025				Healthcare Biotechnology	NTLA-2001	None	NTLA-2001 Fast Track 2022	Phase 3 Data Readout Q1 2026
Nuvation Bio Inc.		650M		1.65 2.5% - 7%	\$3.20 - 01:58 PM EDT 06/10/2025		Stable		Healthcare Biotechnology	·	None	None	Phase 2 Data Readout Q4 2025
NUVL Nuvalent Inc.		5.2B		1.54 2% - 6%		-	Increase		Healthcare Biotechnology		None	None	Phase 2 Data Readout Q2 2026
Novo Nordisk A/S OABI OmniAb Inc.		580B 600M	1.8M 300K	1.23 1.8% - 5% 1.45 2% - 6%	\$130.20 - 01:58 PM EDT 06/10/2025 \$5.20 - 01:58 PM EDT 06/10/2025	0	Stable Stable		Healthcare Biotechnology Healthcare Biotechnology		Ozempic Mar 2017 Wegovy Jun 2021 Rybelsus Sep 2019 None	Ozempic Fast Track 2016 None	Phase 3 Data Readout CagriSema Q1 2026 None
OCUL Ocular Therapeutix	x Inc.	650M	700K	1.45 2% - 6% 1.87 2.8% - 7.5%	·				Healthcare Biotechnology	Dextenza	Dextenza Dec 2018	Dextenza Fast Track 2018	Phase 3 Data Readout AXPAXLI Q4 2025
OLMA Olema Pharmaceut		600M	500K	1.92 3.2% - 8.5%	\$12.80 - 01:58 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	Palazestrant	None None	None	Phase 3 Data Readout Q1 2026
OMER Omeros Corporation		200M		2.01 3.5% - 9%	\$3.50 - 01:58 PM EDT 06/10/2025		Decrease		Healthcare Biotechnology		None	Narsoplimab Fast Track 2020	Phase 3 Data Readout Q4 2025
ORIC Pharmaceution		350M	400K	1.76 2.8% - 7.5%	\$8.50 - 01:58 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	ORIC-114	None	None	Phase 1 Data Readout Q4 2025
OSCR Oscar Health Inc.		4.8B	1.5M	1.54 2% - 6%	\$20.50 - 01:58 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Commercial	Healthcare Health Insurance	e N/A	N/A	N/A	Commercial Expansion Q4 2025
OSMT Osmotica Pharmac	ceuticals plc	150M		1.87 3% - 8%	\$2.20 - 01:58 PM EDT 06/10/2025		Decrease		Healthcare Biotechnology	Upneeq	Upneeq Jul 2020	Upneeq Fast Track 2020	Commercial Expansion Q4 2025
PBYI Puma Biotechnolog	gy Inc.	200M		2.01 3.5% - 9%	·		Stable		Healthcare Biotechnology	Nerlynx	Nerlynx Jul 2017	Nerlynx Fast Track 2016	Phase 2 Data Readout Q3 2026
Vaxcyte Inc.		4.5B	600K	1.65 2.5% - 7%			Increase		Healthcare Biotechnology	VAX-24	None	VAX-24 Fast Track 2023	Phase 3 Data Readout Q1 2026
PDSB PDS Biotechnology Procing Inc.	y Corporation	200M		1.92 3.2% - 8.5%	·		Increase		Healthcare Biotechnology	PDS0101	None	PDS0101 Fast Track 2021	Phase 2 Data Readout Q4 2025
PHAR Pharming Group N		150M		2.01 3.5% - 9% 1.76 2.8% - 7.5%			Decrease Stable		Healthcare Biotechnology Healthcare Biotechnology	PRGN-2012	None	PRGN-2012 Fast Track 2022	Phase 2 Data Readout Q4 2025 Commercial Expansion Q4 2025
PHAR Pharming Group N. PHAT Phathom Pharmace		350M 600M	200K 500K	1.76 2.8% - 7.5% 1.87 3% - 8%			Stable Increase		Healthcare Biotechnology Healthcare Biotechnology	Leniolisib Voquezna	Joenja Apr 2023 Voquezna Aug 2024	Joenja Fast Track 2022 Voquezna Fast Track 2023	Commercial Expansion Q4 2025 Commercial Expansion Q4 2025
PHVS Pharvaris N.V.	Candalo IIIO.	450M	300K	1.87 3% - 8%	\$12.80 - 02:01 PM EDT 06/10/2025 \$18.50 - 02:01 PM EDT 06/10/2025		Stable		Healthcare Biotechnology	Deucrictibant	None	Deucrictibant Fast Track 2023	Phase 3 Data Readout Q1 2026
PLRX Pliant Therapeutics	s Inc.	650M		1.92 3.2% - 8.5%	\$12.20 - 02:01 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	Bexotegrast	None	Bexotegrast Fast Track 2022	Phase 2b Data Readout Q4 2025
PLUR Pluristem Therapeu		80M		2.10 3.5% - 9%	\$5.50 - 02:01 PM EDT 06/10/2025		Decrease		Healthcare Biotechnology		None	None	Phase 3 Data Readout Q3 2026
PRME Prime Medicine Inc		350M		1.76 2.8% - 7.5%			Stable		Healthcare Biotechnology		None	None	Phase 1 Data Readout Q4 2025
PRTA Prothena Corporati	tion plc	1.2B	600K	1.65 2.5% - 7%	\$22.50 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Increase	Clinical	Healthcare Biotechnology	PRX012	None	None	Phase 2 Data Readout Q2 2026
PTCT PTC Therapeutics I	Inc.	2.5B	700K	1.54 2% - 6%	\$35.80 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase	Stable	Commercial	Healthcare Biotechnology	Emflaza Upstaza	Emflaza Apr 2017 Upstaza (EU Approved 2022)	Emflaza Fast Track 2016	Phase 3 Data Readout Vatiquinone Q1 2026
PTGX Protagonist Therap	peutics Inc.	1.8B	500K	1.87 2.8% - 7.5%	\$35.20 - 02:01 PM EDT 06/10/2025				Healthcare Biotechnology	Rusfertide	None	Rusfertide Fast Track 2023	Phase 3 Data Readout Q4 2025
uniQure N.V.		350M		1.92 3.2% - 8.5%	\$5.50 - 02:01 PM EDT 06/10/2025		Decrease .		Healthcare Biotechnology	AMT-130	None	AMT-130 Fast Track 2021	Phase 1/2 Data Readout Q3 2026
RARE Ultragenyx Pharma		4.2B	700K	1.65 2.5% - 7%		0	Increase		Healthcare Biotechnology	Mepsevii Crysvita Dojolvi	Mepsevii Nov 2017 Crysvita Apr 2018 Dojolvi Jun 2020	Mepsevii Fast Track 2017	Phase 3 Data Readout UX701 Q2 2026
RCKT Rocket Pharmaceu RCUS Arcus Biosciences		1.5B 1.2B	600K 800K	1.76 2.8% - 7.5% 1.87 3% - 8%	\$20.80 - 02:01 PM EDT 06/10/2025 \$15.80 - 02:01 PM EDT 06/10/2025		Increase		Healthcare Biotechnology Healthcare Biotechnology	RP-L201 Etrumadenant	None	RP-L201 Fast Track 2021 None	Phase 2 Data Readout Q1 2026 Phase 2 Data Readout Q4 2025
REGN Regeneron Pharma		115B	500K	1.23 1.8% - 5%	\$1050.20 - 02:01 PM EDT 06/10/2025		Stable		Healthcare Biotechnology	Eylea Dupixent	Eylea Aug 2011 Dupixent Mar 2017	Dupixent Fast Track 2016	Phase 3 Data Readout Odronextamab Q1 202
REPL Replimune Group II		350M	700K	1.92 3.2% - 8.5%	\$8.50 - 02:01 PM EDT 06/10/2025	-	Increase		Healthcare Biotechnology	, ,	None	None	Phase 2 Data Readout Q4 2025
REGENXBIO Inc.		600M		1.76 2.8% - 7.5%	\$12.80 - 02:01 PM EDT 06/10/2025				Healthcare Biotechnology	RGX-121	None	RGX-121 Fast Track 2021	Phase 3 Data Readout Q2 2026
RIGL Rigel Pharmaceutic	cals Inc.	200M	1.1M	2.01 3.5% - 9%	\$1.20 - 02:01 PM EDT 06/10/2025	No	Decrease	Commercial	Healthcare Biotechnology	Rezlidhia	Rezlidhia Dec 2022	Rezlidhia Fast Track 2022	Commercial Expansion Q4 2025
RLAY Relay Therapeutics	s Inc.	650M	700K	1.87 3% - 8%	\$8.50 - 02:01 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	RLY-2608	None	None	Phase 1 Data Readout Q4 2025
RNA Avidity Biosciences	s Inc.	2.5B		1.76 2.8% - 7.5%	\$38.50 - 02:01 PM EDT 06/10/2025	Yes - Large Purchase	Increase	Clinical	Healthcare Biotechnology		None	AOC 1001 Fast Track 2022	Phase 2 Data Readout Q1 2026
RPRX Royalty Pharma plo		12.5B		1.34 1.8% - 5%		Yes - Moderate Purchase			Healthcare Biotechnology		Multiple Royalty Agreements	None	Commercial Expansion Q4 2025
Revolution Medicin		3.5B	700K	1.65 2.5% - 7%	\$45.20 - 02:01 PM EDT 06/10/2025	Yes - Moderate Purchase			Healthcare Biotechnology	RMC-6236	None	None	Phase 1 Data Readout Q4 2025
RXRX Recursion Pharmace		650M 2.8B		1.92 3.2% - 8.5% 1.54 2% - 6%	\$8.80 - 02:01 PM EDT 06/10/2025 \$48.50 - 02:01 PM EDT 06/10/2025	No Yes - Large Purchase	Stable Increase		Healthcare Biotechnology Healthcare Biotechnology	REC-994 Imcivree	None Imcivree Nov 2020	None Imcivree Fast Track 2020	Phase 2 Data Readout Q3 2026 Phase 3 Data Readout LB54640 Q2 2026
RYTM Rhythm Pharmacet RZLT Rezolute Inc.	atioais IIIO.	2.8B 200M		1.54 2% - 6% 2.01 3.5% - 9%	\$48.50 - 02:01 PM EDT 06/10/2025 \$3.80 - 02:01 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	RZ358	None	None	Phase 3 Data Readout LB54640 Q2 2026 Phase 2 Data Readout Q4 2025
SAGE Sage Therapeutics	s Inc.	650M		1.87 2.8% - 7.5%	·		Stable		Healthcare Biotechnology	Zuranolone	Zulresso Mar 2019 Zurzuvae Aug 2023	Zuranolone Fast Track 2022	Phase 3 Data Readout SAGE-324 Q2 2026
SANA Sana Biotechnolog		1.5B	700K	1.92 3.2% - 8.5%	\$6.80 - 02:15 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	SC291	None	None	Phase 1 Data Readout Q4 2025
Sangamo Therapeu	utics Inc.	200M	1.5M	2.01 3.5% - 9%	\$0.80 - 02:15 PM EDT 06/10/2025	No	10% Decrease	Clinical	Healthcare Biotechnology	SB-525	None	None	Phase 3 Data Readout Q4 2025
Solid Biosciences I	Inc.	350M	400K	1.76 2.8% - 7.5%	\$3.50 - 02:15 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	SGT-003	None	SGT-003 Fast Track 2024	Phase 1/2 Data Readout Q1 2025
Soleno Therapeutic		2.8B	600K	1.65 2.5% - 7%		0	Increase		Healthcare Biotechnology	DCCR	None	DCCR Fast Track 2023	FDA Decision Q3 2025
SMMT Summit Therapeuti		2.5B		1.87 3% - 8%	\$12.80 - 02:15 PM EDT 06/10/2025				Healthcare Biotechnology	Ivonescimab	None	None	Phase 3 Data Readout Q2 2026
STOK Stoke Therapeutics		650M		1.54 2% - 6% 1.85 3.2% - 8.5%	\$10.50 - 02:15 PM EDT 06/10/2025 \$15.20 - 02:15 PM EDT 06/10/2025		Stable Ves - Moderate Pure		Healthcare Biotechnology	Neffy STK-001	Neffy Aug 2024	Neffy Fast Track 2023	Commercial Expansion Q4 2025 Phase 2 Data Readout O1 2025
STOK Stoke Therapeutics SYRE Spyre Therapeutics		600M 1.2B	400K 300K	1.85 3.2% - 8.5% 1.76 2.8% - 7.5%	\$15.20 - 02:15 PM EDT 06/10/2025 \$28.50 - 02:15 PM EDT 06/10/2025		Yes - Moderate Purc		Healthcare Biotechnology Healthcare Biotechnology	STK-001 SPY001	None	STK-001 Fast Track 2021 None	Phase 2 Data Readout Q1 2025 Phase 1 Data Readout Q4 2025
TCRX TScan Therapeutics		350M		1.76 2.8% - 7.5%	\$6.80 - 02:15 PM EDT 06/10/2025		Stable		Healthcare Biotechnology		None	None	Phase 1 Data Readout Q4 2025 Phase 1 Data Readout Q3 2026
TGTX TG Therapeutics In		2.8B	1.5M	1.65 2.5% - 7%			Increase		Healthcare Biotechnology	Briumvi	Briumvi Dec 2022	Briumvi Fast Track 2022	Commercial Expansion Q4 2025
THRX Theseus Pharmace		150M	200K	1.92 3.2% - 8.5%	\$4.50 - 02:15 PM EDT 06/10/2025	No	Decrease		Healthcare Biotechnology	THE-630	None	None	Phase 1 Data Readout Q4 2025
Tango Therapeutics	s Inc.	350M	400K	1.76 2.8% - 7.5%	\$8.50 - 02:15 PM EDT 06/10/2025	No	Stable	Clinical	Healthcare Biotechnology	TNG908	None	None	Phase 1 Data Readout Q3 2026
Tourmaline Bio Inc.		650M	300K	1.65 2.5% - 7%	<u> </u>	Yes - Moderate Purchase	Increase		Healthcare Biotechnology	TOUR006	None	None	Phase 2 Data Readout Q1 2026
Viking Therapeutics		5.5B		1.54 2% - 6%	\$65.20 - 02:15 PM EDT 06/10/2025	C .	Increase		Healthcare Biotechnology		None	VK2735 Fast Track 2024	Phase 3 Data Readout Q1 2026
/RDN Viridian Therapeution		650M		1.87 3% - 8%	·	Yes - Moderate Purchase			Healthcare Biotechnology		None	VRDN-001 Fast Track 2023	Phase 3 Data Readout Q4 2025
Verona Pharma plc	;	2.2B	600K	1.65 2.5% - 7%	<u>'</u>	Yes - Moderate Purchase			Healthcare Biotechnology	Ensifentrine	Ohtuvayre Jun 2024	Ohtuvayre Fast Track 2023	Commercial Expansion Q4 2025
/STM Verastem Inc. /YGR Voyager Therapeut	utics Inc	200M 350M		2.01 3.5% - 9% 1.76 2.8% - 7.5%	·		Stable Stable		Healthcare Biotechnology Healthcare Biotechnology	Avutometinib VY-TAU01	None	None	Phase 2 Data Readout Q4 2025 Phase 1 Data Readout Q3 2026
VVE Wave Life Sciences		350M 650M	400K 600K	1.76 2.8% - 7.5% 1.92 3.2% - 8.5%		Yes - Moderate Purchase No	Stable	Clinical	Healthcare Biotechnology Healthcare Biotechnology	VY-IAU01 WVE-006	None	None WVE-006 Fast Track 2024	Phase 1 Data Readout Q3 2026 Phase 2 Data Readout Q1 2026
Trave Life Sciences		2.8B		1.92 3.2% - 8.5%	\$45.50 - 02:11 PM EDT 06/10/2025		Increase		Healthcare Biotechnology	Azatirionant	None	None	Phase 2 Data Readout Q1 2026 Phase 3 Data Readout Q4 2025
ENE Xenon Pharmaceut		350M		1.87 3% - 8%		Yes - Moderate Purchase			Healthcare Biotechnology	Levoketoconazole	Keveyis Aug 2015 Gvoke Sep 2019 Recorlev Dec 2021	Keveyis Fast Track 2014	Commercial Expansion Q4 2025
Xenon Pharmaceut Xeris Biopharma Ho		350M		1.92 3.2% - 8.5%			Increase		Healthcare Biotechnology		None	Azenosertib Fast Track 2023	Phase 2 Data Readout Q3 2026
	auticals Inc.						Decrease		Healthcare Biotechnology		None	None	Phase 2 Data Readout Q4 2025
KERS Xeris Biopharma Ho		150M	400K	2.01 3.5% - 9%	\$2.20 - 02:11 PM EDT 06/10/2025	No	Deorease	Cililical	Treatmoure Dioteormology			T. Control of the Con	
Xeris Biopharma Ho ZNTL Zentalis Pharmace	cals Inc.	150M 350M		2.01 3.5% - 9% 1.65 2.5% - 7%	\$2.20 - 02:11 PM EDT 06/10/2025 \$28.50 - 02:11 PM EDT 06/10/2025						Multiple Royalty Agreements	None	Commercial Expansion Q4 2025
Xeris Biopharma Ho ZNTL Zentalis Pharmaceutic PMVP PMV Pharmaceutic	icals Inc.		200K			Yes - Moderate Purchase		Commercial			Multiple Royalty Agreements Azstarys Mar 2021	None Azstarys Fast Track 2020	Commercial Expansion Q4 2025 Commercial Expansion Q4 2025

Partners	Space	Competitors	Cash Rupway	Last Farnings Date	Last_Earnings_Result	Next_Earnings_Date	Ratina	SA Rating	Country
Lilly (LLY) Pfizer (PFE)	Antibody Discovery	Amgen (AMGN) Regeneron (REGN)	24 months	May 7 2025	EPS -0.14 -6% Miss Revenue 9.8M -10% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	Canada
None AstraZeneca (AZN) Merck (MRK)	Gene Therapy Al-Driven Drug Discovery	Krystal Biotech (KRYS) Schrodinger (SDGR) Recursion (RXRX)	18 months 20 months	May 6 2025 May 8 2025	EPS -0.45 -8% Miss Revenue 0.3M -20% Miss EPS -0.22 -5% Miss Revenue 1.8M +10% Beat	Aug 4 2025 (est.) Aug 6 2025 (est.)	5 (B-) 7 (B+)	HOLD BUY	USA
None None	HBV Therapy	Gilead (GILD) Moderna (MRNA)	15 months	May 2 2025	EPS -0.12 -10% Miss Revenue 1.5M -15% Miss	Jul 31 2025 (est.)	6 (B)	HOLD	Canada
None Regeneron (REGN)	CNS Disorders Cell Therapy	Eisai (ESALY) Biogen (BIIB) Allogene (ALLO) Fate Therapeutics (FATE)	30 months 12 months	May 8 2025 May 7 2025	EPS 0.10 +15% Beat Revenue 205.8M +8% Beat EPS -0.36 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	8 (A-) 5 (B-)	BUY	USA
Kite/Gilead (GILD)	Cell Therapy	Allogene (ALLO) Caribou (CRBU)	24 months	May 9 2025	EPS -0.50 -5% Miss Revenue 21.3M +12% Beat	Aug 7 2025 (est.)	7 (B+)	BUY	USA
None GSK (GSK)	Dermatology T-Cell Therapy	Incyte (INCY) Dermavant Immunocore (IMCR) TCR2	12 months 15 months	May 7 2025 May 8 2025	EPS -0.15 -10% Miss Revenue 2.4M -8% Miss EPS -0.18 -15% Miss Revenue 5.9M -10% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	5 (B-) 6 (B)	HOLD	USA
Genentech (RHHBY)	Immunosequencing	Illumina (ILMN) 10x Genomics (TXG)	18 months	May 7 2025	EPS -0.34 -8% Miss Revenue 41.5M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None BMS (BMY) Merck (MRK)	Immuno-Oncology	CSL Behring (CSLLY) Grifols (GRFS) Incyte (INCY) Regeneron (REGN)	36 months 12 months	May 9 2025 May 7 2025	EPS 0.08 +20% Beat Revenue 81.9M +10% Beat EPS -0.22 -18% Miss Revenue 37.2M -5% Miss	Aug 7 2025 (est.) Aug 5 2025 (est.)	8 (A-) 5 (B-)	BUY SELL	USA
Servier	Oncology	Servier Bristol Myers (BMY)	24 months	May 2 2025	EPS -1.65 -10% Miss Revenue 8.2M +15% Beat	Jul 31 2025 (est.)	7 (B+)	BUY	USA
None GSK (GSK)	Ophthalmology Neurodegenerative Diseases	Allergan (ABBV) Bausch (BHC) Denali (DNLI) Biogen (BIIB)	18 months 20 months	May 7 2025 May 8 2025	EPS -0.28 -12% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 15.1M -8% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B)	HOLD	USA
Pfizer (PFE) Regeneron (REGN) Sanofi (SNY)	Cell Therapy RNAi Therapeutics	Arcellx (ACLX) Kite/Gilead (GILD) Arrowhead (ARWR) Ionis (IONS)	18 months 36 months	May 7 2025 May 2 2025	EPS -0.38 -7% Miss Revenue 0.0M N/A EPS -0.75 +5% Beat Revenue 494.7M +12% Beat	Aug 5 2025 (est.) Jul 31 2025 (est.)	6 (B) 9 (A)	HOLD STRONG BUY	USA
Fosun Pharma	Generics		N/A	May 8 2025	EPS 0.14 +10% Beat Revenue 659.2M +8% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	USA
None GSK (GSK)	NASH Immunology	Madrigal (MDGL) Intercept (ICPT) Regeneron (REGN) Amgen (AMGN)	24 months 18 months	May 7 2025 May 9 2025	EPS -0.85 -12% Miss Revenue 0.0M N/A EPS -1.60 -15% Miss Revenue 10.4M -10% Miss	Aug 5 2025 (est.) Aug 7 2025 (est.)	7 (B+) 6 (B)	BUY	USA
None	Neurodegenerative Diseases	Alector (ALEC) Denali (DNLI)	12 months	May 7 2025	EPS -0.95 -20% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Swedish Orphan (SOBI) None	Ophthalmology RNA Therapeutics	Regeneron (REGN) Roche (RHHBY) Alnylam (ALNY) Moderna (MRNA)	30 months 18 months	May 7 2025 May 8 2025	EPS -0.55 +8% Beat Revenue 162.5M +10% Beat EPS -0.40 -10% Miss Revenue 2.1M -12% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 6 (B)	BUY	USA
Kyowa Kirin	GI Disorders	Salix Ironwood (IRWD)	24 months	May 2 2025	EPS -0.09 +12% Beat Revenue 46.0M +15% Beat	Jul 31 2025 (est.)	8 (A-)	BUY	USA
Janssen (JNJ) Zai Lab None	Immunology Bacteriophage Therapy	Amgen (AMGN) Regeneron (REGN) ContraFect (CFRX)	36 months 12 months	May 9 2025 May 7 2025	EPS -1.05 +10% Beat Revenue 412.3M +12% Beat EPS -0.45 -15% Miss Revenue 0.0M N/A	Aug 7 2025 (est.) Aug 5 2025 (est.)	9 (A) 5 (B-)	STRONG BUY	Netherlands USA
None	Dermatology	Incyte (INCY) Dermavant	24 months	May 8 2025	EPS -0.55 +10% Beat Revenue 21.6M +12% Beat	Aug 6 2025 (est.)	, ,	BUY	USA
Pfizer (PFE) Gilead (GILD)	PROTAC Technology HBV Therapy	Amgen (AMGN) Kymera (KYMR) Arbutus (ABUS) Gilead (GILD)	18 months 12 months	May 7 2025 May 8 2025	EPS -0.95 -10% Miss Revenue 25.3M +8% Beat EPS -0.35 -12% Miss Revenue 6.2M -5% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 5 (B-)	HOLD SELL	USA
None	Endocrinology	Novo Nordisk (NVO) Pfizer (PFE)	30 months	May 2 2025	EPS -1.35 +8% Beat Revenue 95.4M +10% Beat	Jul 31 2025 (est.)	8 (A-)	BUY	Denmark
None	Neurodegenerative Diseases Hereditary Angioedema	Alector (ALEC) Annovis (ANVS) Takeda (TAK) CSL Behring	12 months 18 months	May 7 2025 May 9 2025	EPS -0.65 -15% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 7 2025 (est.)	5 (B-) 6 (B)	SELL HOLD	USA
None	Pulmonary Sarcoidosis	Keros (KROS)	12 months	May 7 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None Otsuka	Ocular Oncology Lupus Nephritis	Immunocore (IMCR) GSK (GSK) Calliditas (CALT)	18 months 24 months	May 8 2025 May 2 2025	EPS -0.50 -8% Miss Revenue 0.0M N/A EPS -0.15 +12% Beat Revenue 50.3M +10% Beat	Aug 6 2025 (est.) Jul 31 2025 (est.)	6 (B) 7 (B+)	HOLD	USA Canada
Roche (RHHBY) None	Antiviral Therapy Neurodegenerative Diseases	Gilead (GILD) Merck (MRK) Biogen (BIIB) Alector (ALEC)	18 months	May 7 2025 May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.15 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B)	HOLD HOLD	USA
Pfizer (PFE)	CNS Disorders	Jazz (JA3Z) Alkermes (ALKS)	15 months 30 months	May 7 2025	EPS -1.25 +10% Beat Revenue 74.8M +12% Beat	Aug 5 2025 (est.)	6 (B) 8 (A-)	BUY	USA
BMS (BMY) None	Cardiomyopathy Head and Neck Cancer	Alnylam (ALNY) Pfizer (PFE) Incyte (INCY) Merck (MRK)	24 months 20 months	May 9 2025 May 8 2025	EPS -0.95 -10% Miss Revenue 20.5M +8% Beat EPS -0.40 -12% Miss Revenue 0.0M N/A	Aug 7 2025 (est.) Aug 6 2025 (est.)	7 (B+) 6 (B)	BUY	USA
None	Hereditary Angioedema	Astria (ATXS) Takeda (TAK)	24 months	May 7 2025	EPS -0.20 +8% Beat Revenue 92.4M +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Pfizer (PFE) Verve (VERV) Eisai (ESALY)	Gene Editing Neurodegenerative Diseases	CRISPR (CRSP) Intellia (NTLA) Eli Lilly (LLY) Roche (RHHBY)	18 months	May 7 2025 May 2 2025	EPS -1.05 -10% Miss Revenue 10.2M -5% Miss EPS 3.85 +15% Beat Revenue 2.4B +5% Beat	Aug 5 2025 (est.) Jul 31 2025 (est.)	6 (B) 8 (A-)	HOLD	USA
None	Hematology	Amgen (AMGN) Jazz (JAZZ)	12 months	May 8 2025	EPS -0.10 -8% Miss Revenue 6.8M +10% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	Israel
None	Oncology Rare Diseases	Incyte (INCY) Merck (MRK) Ultragenyx (RARE) Sarepta (SRPT)	15 months N/A	May 7 2025 May 2 2025	EPS -0.75 -12% Miss Revenue 0.0M N/A EPS 0.45 +12% Beat Revenue 650.3M +8% Beat	Aug 5 2025 (est.) Jul 31 2025 (est.)	6 (B) 8 (A-)	HOLD	USA
Pfizer (PFE)	mRNA Vaccines	, , , , ,	N/A	May 7 2025	EPS -1.05 +10% Beat Revenue 1.2B +5% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	Germany
Roche (RHHBY) None	Precision Oncology Neuropsychiatric Disorders	Amgen (AMGN) Loxo (LLY) Axsome (AXSM) Jazz (JAZZ)	30 months 12 months	May 7 2025 May 8 2025	EPS -1.45 +8% Beat Revenue 85.6M +10% Beat EPS -0.65 -15% Miss Revenue 0.4M -20% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 5 (B-)	BUY SELL	USA
None	Oncology	Immunocore (IMCR) Agenus (AGEN)	12 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	, ,	HOLD	USA
None Nippon Shinyaku	Oncology Cardiomyopathy	Incyte (INCY) Merck (MRK) BridgeBio (BBIO) Alnylam (ALNY)	12 months 15 months	May 8 2025 May 7 2025	EPS -0.15 -12% Miss Revenue 0.0M N/A EPS -0.30 -8% Miss Revenue 4.2M +10% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.)	5 (B-) 6 (B)	SELL HOLD	USA
Pfizer (PFE)	Oncology	Amgen (AMGN) Pfizer (PFE)	18 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Cell Therapy Regenerative Medicine	Allogene (ALLO) Arcellx (ACLX) Lineage Cell (LCTX)	12 months 12 months	May 7 2025 May 8 2025	EPS -0.25 -15% Miss Revenue 2.1M -10% Miss EPS -0.20 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	5 (B-) 4 (C)	SELL	USA
None Taile Oracles	Immunology	Regeneron (REGN) AnaptysBio (ANAB)	24 months	May 7 2025	EPS -0.60 -8% Miss Revenue 0.9M +5% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Taiho Oncology None	Oncology Bladder Cancer	Amgen (AMGN) Blueprint (BPMC) ImmunityBio (IBRX) Merck (MRK)	18 months 24 months	May 8 2025 May 7 2025	EPS -0.90 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B) 7 (B+)	HOLD	USA
None	Neurodegenerative Diseases	Annovis (ANVS) Alector (ALEC)	12 months	May 8 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Biosimilars Oncology	Amgen (AMGN) Viatris (VTRS) Regeneron (REGN) Bristol Myers (BMY)	18 months 12 months	May 7 2025 May 8 2025	EPS -0.15 +10% Beat Revenue 77.2M +8% Beat EPS -0.30 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 5 (B-)	HOLD SELL	USA
None Allogene (ALLO)	Ophthalmology Cell Therapy	Regeneron (REGN) Bausch (BHC) Allogene (ALLO) Arcellx (ACLX)	12 months 15 months	May 7 2025 May 8 2025	EPS -0.15 -12% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 1.8M -5% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	5 (B-) 5 (B-)	HOLD SELL	USA France
None None	Oncology	Amgen (AMGN) Incyte (INCY)	12 months	May 7 2025	EPS -0.25 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
None	Hemophilia Oncology	CSL Behring Novo Nordisk (NVO) Blueprint (BPMC) Amgen (AMGN)	20 months 18 months	May 8 2025 May 7 2025	EPS -0.40 -10% Miss Revenue 0.0M N/A EPS -0.55 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B)	BUY	UK
None	Neurodegenerative Diseases	Annovis (ANVS) Alector (ALEC)	15 months	May 8 2025	EPS -0.30 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None BioMarin (BMRN) Endo Ventures	Endocrinology Rare Diseases	Pfizer (PFE) Novo Nordisk (NVO) BioMarin (BMRN) Ultragenyx (RARE)	N/A N/A	May 7 2025 May 8 2025	EPS 0.25 +15% Beat Revenue 146.8M +10% Beat EPS 0.45 +20% Beat Revenue 141.4M +15% Beat	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 8 (A-)	BUY STRONG BUY	USA
None	Oncology	Amgen (AMGN) Merck (MRK)	18 months	May 7 2025	EPS -0.20 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	BUY	USA
None	Oncology Antimicrobial Therapy	Incyte (INCY) Blueprint (BPMC) Becton Dickinson (BDX)	12 months	May 8 2025 May 7 2025	EPS -0.25 -10% Miss Revenue 2.5M -5% Miss EPS -0.15 +10% Beat Revenue 0.8M +12% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.)	5 (B-) 6 (B)	SELL	USA
None	Endocrinology	Ascendis (ASND) Amgen (AMGN)	24 months	May 8 2025	EPS -0.85 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B+)	BUY	USA
Vertex (VRTX) Amgen (AMGN)	Gene Editing Oncology	Beam (BEAM) Intellia (NTLA) Regeneron (REGN) Bristol Myers (BMY)	24 months 12 months	May 7 2025 May 8 2025	EPS -1.45 -10% Miss Revenue 0.5M -8% Miss EPS -0.15 -12% Miss Revenue 25.2M +10% Beat	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 5 (B-)	HOLD	Switzerland
None	Cardiomyopathy	BridgeBio (BBIO) Alnylam (ALNY)	24 months	May 7 2025	EPS -1.35 -10% Miss Revenue 0.9M -5% Miss	Aug 5 2025 (est.)	, ,	BUY	USA
None Biogen (BIIB) Sanofi (SNY)	Pediatric Oncology Neurodegenerative Diseases	Blueprint (BPMC) Loxo (LLY) Alector (ALEC) Annovis (ANVS)	18 months 24 months	May 8 2025 May 7 2025	EPS -0.65 -8% Miss Revenue 8.2M +12% Beat EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	7 (B+) 7 (B+)	BUY	USA
None	Vaccines	GSK (GSK) Moderna (MRNA)	N/A	May 8 2025	EPS 0.05 +15% Beat Revenue 75.6M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None Bayer Animal Health	Gene Editing Animal Health	CRISPR (CRSP) Beam (BEAM) Zoetis (ZTS) Merck Animal Health	15 months N/A	May 7 2025 May 7 2025	EPS -0.80 -12% Miss Revenue 7.1M -5% Miss EPS 0.20 +12% Beat Revenue 1.2B +8% Beat	Aug 5 2025 (est.) Aug 5 2025 (est.)	6 (B) 8 (A-)	HOLD	USA
None	Oncology	Cullinan (CGEM) Incyte (INCY)	12 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Oncology Antiviral Therapy	Blueprint (BPMC) Amgen (AMGN) Atea (AVIR) Gilead (GILD)	20 months 18 months	May 7 2025 May 8 2025	EPS -0.45 -8% Miss Revenue 0.0M N/A EPS -1.25 -10% Miss Revenue 17.8M -5% Miss	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B)	BUY HOLD	USA
None Janssen (JNJ)	Aesthetics Oncology	Allergan (ABBV) Galderma Pfizer (PFE) Astellas (ALPMY)	N/A 15 months	May 7 2025 May 8 2025	EPS -0.10 +10% Beat Revenue 59.3M +12% Beat EPS -0.35 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	7 (B+) 5 (B-)	BUY	USA Canada
Novartis (NVS)	Oncology	Blueprint (BPMC) Amgen (AMGN)	18 months	May 7 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	BUY	USA
None BMS (BMY) Sanofi (SNY)	NASH Al-Driven Drug Discovery	Akero (AKRO) Madrigal (MDGL) Absci (ABSI) Recursion (RXRX)	20 months 18 months	May 8 2025 May 7 2025	EPS -0.55 -8% Miss Revenue 0.0M N/A EPS -0.40 -10% Miss Revenue 10.5M -5% Miss	Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B)	BUY	USA
BMS (BMY) Roche (RHHBY)	Oncology	Amgen (AMGN) Pfizer (PFE)	N/A	May 7 2025	EPS 0.35 +15% Beat Revenue 425.2M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Arctic Vision None	Ophthalmology Ophthalmology	Apellis (APLS) Bausch (BHC) Regeneron (REGN) Apellis (APLS)	12 months 18 months	May 8 2025 May 7 2025	EPS -0.20 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 11.8M +10% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.)	5 (B-) 6 (B)	HOLD	USA
UniQure (QURE)	Gene Therapy	Abeona (ABEO) Krystal (KRYS)	20 months	May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
AstraZeneca (AZN) None	Fibrosis Rare Diseases	Akero (AKRO) 89bio (ETNB) BioMarin (BMRN) Ultragenyx (RARE)	12 months N/A	May 7 2025 May 8 2025	EPS -0.30 -12% Miss Revenue 36.4M -5% Miss EPS -0.05 +12% Beat Revenue 110.5M +10% Beat	Aug 5 2025 (est.) Aug 6 2025 (est.)	5 (B-) 8 (A-)	SELL	USA
None	Clinical Research Services	Labcorp (LH) IQVIA (IQV)	N/A	May 7 2025	EPS 0.25 +10% Beat Revenue 775.3M +8% Beat	Aug 5 2025 (est.)	, ,	BUY	USA
None	Rare Diseases Hematology	Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Amgen (AMGN)	18 months 24 months	May 8 2025 May 7 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.10 +8% Beat Revenue 0.3M +10% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B) 7 (B+)	BUY	USA
Arcus Biosciences Merck (MRK)		Amgen (AMGN) Pfizer (PFE)	N/A	May 7 2025	EPS 1.85 +15% Beat Revenue 6.7B +8% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Gilead (GILD) None	Immunology Breast Cancer	Incyte (INCY) AbbVie (ABBV) SELLAS (SLS) Merck (MRK)	18 months 15 months	May 8 2025 May 7 2025	EPS -0.35 -10% Miss Revenue 65.2M +5% Beat EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B) 5 (B-)	HOLD	Belgium
None	Hematology	Jazz (JAZZ) Amgen (AMGN)	12 months	May 8 2025	EPS -0.15 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
Janssen (JNJ) AbbVie (ABBV) None	Oncology NASH	Amgen (AMGN) Regeneron (REGN) Akero (AKRO) 89bio (ETNB)	N/A 15 months	May 7 2025 May 8 2025	EPS 0.35 +12% Beat Revenue 650.3M +10% Beat EPS -0.20 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 5 (B-)	BUY HOLD	Denmark USA
Roche (RHHBY) Pfizer (PFE)	Drug Delivery	Janssen (JNJ) Amgen (AMGN)	N/A	May 7 2025	EPS 0.85 +15% Beat Revenue 235.4M +12% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Gilead (GILD) None	Oncology Narcolepsy	Moderna (MRNA) Merck (MRK) Jazz (JAZZ) Axsome (AXSM)	12 months N/A	May 8 2025 May 7 2025	EPS -0.15 -10% Miss Revenue 4.2M -5% Miss EPS 0.45 +10% Beat Revenue 168.3M +12% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.)	5 (B-) 8 (A-)	SELL	USA
None GSK (GSK) Pfizer (PFE)	NASH Oncology	Madrigal (MDGL) Akero (AKRO) Amgen (AMGN) Blueprint (BPMC)	N/A 20 months	May 8 2025 May 7 2025	EPS -0.25 +8% Beat Revenue 85.6M +10% Beat EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	, ,	HOLD	USA
None	Oncology Ocular Oncology	Amgen (AMGN) Blueprint (BPMC) Aura (AURA)	20 months 24 months	May 7 2025 May 7 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.45 +8% Beat Revenue 75.4M +10% Beat	Aug 5 2025 (est.) Aug 5 2025 (est.)	, ,	BUY	UK
None	Oncology Oncology	Incyte (INCY) Merck (MRK) Amgen (AMGN) Regeneron (REGN)	12 months 18 months	May 8 2025 May 7 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.)	5 (B-) 6 (B)	HOLD BUY	USA
None	Immunology	Argenx (ARGX) Regeneron (REGN)	24 months	May 8 2025	EPS -0.35 -8% MISS Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B) 7 (B+)	BUY	USA
Sanofi (SNY) None	Rare Diseases Oncology Dermatology	Amicus (FOLD) BioMarin (BMRN) Amgen (AMGN) Merck (MRK)	15 months	May 7 2025 May 7 2025	EPS -0.65 -12% Miss Revenue 0.0M N/A EPS 0.85 +12% Beat Revenue 1.0B +10% Beat	Aug 5 2025 (est.) Aug 5 2025 (est.)	6 (B) 8 (A-)	HOLD	USA
None	Pulmonary Diseases	Vertex (VRTX) Chiesi	24 months	May 8 2025	EPS -1.15 -8% Miss Revenue 80.7M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
GSK (GSK) None	Respiratory Rare Diseases	GSK (GSK) AstraZeneca (AZN) Amicus (FOLD) BioMarin (BMRN)	N/A 15 months	May 7 2025 May 8 2025	EPS 0.35 +10% Beat Revenue 85.2M +8% Beat EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	7 (B+) 6 (B)	BUY	USA
None	Oncology	Immunocore (IMCR) Bristol Myers (BMY)	24 months	May 7 2025	EPS -0.35 +8% Beat Revenue 31.2M +15% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	CNS Disorders Antiviral Therapy	Axsome (AXSM) Jazz (JAZZ) Atea (AVIR) Gilead (GILD)	N/A 12 months	May 7 2025 May 8 2025	EPS -0.15 +12% Beat Revenue 144.8M +10% Beat EPS -0.25 -10% Miss Revenue 十大网赌正规网址下	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 5 (B-)	BUY	USA
None	Oncology	Amgen (AMGN) Merck (MRK)	20 months	May 7 2025	EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	CNS Disorders Immunology	Harmony (HRMY) Axsome (AXSM) Regeneron (REGN) AnaptysBio (ANAB)	N/A 12 months	May 7 2025 May 8 2025	EPS 4.25 +12% Beat Revenue 970.5M +8% Beat EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	8 (A-) 5 (B-)	BUY	Ireland
None	HAE	CSL Behring BioCryst (BCRX)	15 months	May 7 2025	EPS -0.85 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	Argenx (ARGX) Regeneron (REGN)	20 months	May 7 2025	EPS -0.15 +10% Beat Revenue 85.2M +12% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA

Nicola	O all the december	Decree (DECAN Assetts (ADLO)	40	NA 0 0005	EDO 0.05 400/ Min D 0.0MAN/A	A 0.0005 (I.)	F (D)	OFLI	1104
None	Ophthalmology	Regeneron (REGN) Apellis (APLS)	12 months	May 8 2025	EPS -0.95 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	USA
None	Hematology Oncology	Geron (GERN) Amgen (AMGN) Blueprint (BPMC) Incyte (INCY)	20 months 18 months	May 7 2025 May 8 2025	EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.55 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	7 (B+) 6 (B)	BUY	USA
None	Gene Therapy	Abeona (ABEO) 4DMT (FDMT)	N/A	May 7 2025	EPS 0.25 +15% Beat Revenue 70.3M +10% Beat	Aug 5 2025 (est.)	8 (A-)	BUY	USA
Sanofi (SNY)	Immunology	Regeneron (REGN) AnaptysBio (ANAB)	20 months	May 7 2025	EPS -0.75 -10% Miss Revenue 10.2M -5% Miss	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Janssen (JNJ)	Cell Therapy	Allogene (ALLO) Arcellx (ACLX)	24 months	May 8 2025	EPS -0.35 +8% Beat Revenue 95.4M +12% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	China
None	Ophthalmology	Eyenovia (EYEN) Apellis (APLS)	15 months	May 7 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE) Amgen (AMGN)	Drug Delivery	Halozyme (HALO) Catalent (CTLT)	N/A	May 8 2025	EPS 0.95 +10% Beat Revenue 45.7M +8% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	USA
None	Pulmonary Diseases	Insmed (INSM) United (UTHR)	18 months	May 7 2025	EPS -0.25 +8% Beat Revenue 4.5M +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	15 months	May 8 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Cardiometabolic	AstraZeneca (AZN) Novo Nordisk (NVO)	18 months	May 7 2025	EPS -0.15 -8% Miss Revenue 1.2M +5% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
GSK (GSK)	Cell Therapy	Allogene (ALLO) Arcellx (ACLX)	15 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	HOLD	USA
None	NASH	Akero (AKRO) 89bio (ETNB)	24 months	May 7 2025	EPS -6.25 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	8 (A-)	BUY	USA
None	Cell Therapy	Allogene (ALLO) Celularity (CELU)	18 months	May 8 2025	EPS -0.15 -8% Miss Revenue 7.2M -5% Miss	Aug 6 2025 (est.)	6 (B)	HOLD	Australia
Incyte (INCY)	Oncology	Amgen (AMGN) Regeneron (REGN)	12 months	May 7 2025	EPS -0.35 -12% Miss Revenue 10.8M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Janssen (JNJ)	Gene Therapy	Krystal (KTTA) 4DMT (FDMT)	15 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Moderna (MRNA)	Gene Editing	CRISPR (CRSP) Editas (EDIT)	12 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	24 months	May 7 2025	EPS -0.45 +8% Beat Revenue 77.5M +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Hypertension	AstraZeneca (AZN) Novartis (NVS)	18 months	May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
United (UTHR)	Diabetes	Novo Nordisk (NVO) Eli Lilly (LLY)	N/A	May 7 2025	EPS 0.05 +12% Beat Revenue 65.3M +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	CNS Disorders	Intra-Cellular (ITCI) Axsome (AXSM)	18 months	May 8 2025	EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Ultragenyx (RARE)	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	18 months	May 7 2025	EPS -0.10 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	, ,	HOLD	UK
None	CNS Disorders	Jazz (JAZZ) Axsome (AXSM)	12 months	May 8 2025	EPS -0.65 -10% Miss Revenue 8.2M -5% Miss	Aug 6 2025 (est.)	, ,	SELL	USA
Janssen (JNJ)	Oncology	Amgen (AMGN) Incyte (INCY)	15 months	May 7 2025	EPS -0.25 -10% Miss Revenue 10.5M -5% Miss	Aug 5 2025 (est.)	5 (B-)	HOLD	USA
Incyte (INCY) Lilly (LLY)	Oncology	Regeneron (REGN) Blueprint (BPMC)	20 months	May 8 2025	EPS -0.85 -8% Miss Revenue 10.2M +5% Beat	Aug 6 2025 (est.)	7 (B+)	BUY	Netherlands
None	Oncology	MacroGenics (MGNX) Amgen (AMGN)	12 months	May 7 2025	EPS -0.15 -12% Miss Revenue 7.8M -5% Miss	Aug 5 2025 (est.)	, ,	SELL	USA
None	Cardiovascular	Pfizer (PFE) Amgen (AMGN)	20 months	May 7 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B+)	BUY	Netherlands
None	Proteomics	Seer (SEER) Somalogic	15 months	May 7 2025	EPS -0.15 -8% Miss Revenue 2.3M -5% Miss	Aug 6 2025 (est.)	5 (B-)	HOLD	USA
None Gilead (GILD) Sanofi (SNY)	Oncology	Curis (CRIS) Cullinan (CGEM)	15 months	May 7 2025	EPS -0.35 -10% Miss Revenue 5.4M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	France
Gilead (GILD) Sanofi (SNY)	Oncology Gene Editing	Kura (KURA) Blueprint (BPMC)	18 months	May 7 2025	EPS -0.65 -8% Miss Revenue 12.3M +5% Beat	Aug 6 2025 (est.)	6 (B)	BUY	USA
Regeneron (REGN)	Gene Editing	CRISPR (CRSP) Editas (EDIT) Amgen (AMGN) Pfizer (PFE)	18 months	May 8 2025 May 7 2025	EPS -1.35 -10% Miss Revenue 7.8M -5% Miss EPS -0.15 -8% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY HOLD	USA
None	Oncology	Blueprint (BPMC) Kura (KURA)	18 months	-	EPS -0.15 -8% MISS Revenue 0.0M N/A EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B)	BUY	USA
None	Oncology Diabetes Obesity	Eli Lilly (LLY) Amgen (AMGN)	24 months N/A	May 8 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS 0.85 +15% Beat Revenue 10.2B +12% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.)	8 (A-) 9 (A)	STRONG BUY	
Lilly (LLY) Genmab (GMAB)	Antibody Discovery	Ligand (LGND) Amgen (AMGN)	18 months	May 8 2025	EPS 0.85 +15% Beat Revenue 10.2B +12% Beat EPS -0.15 -8% Miss Revenue 7.5M +5% Beat	Aug 6 2025 (est.)	9 (A) 6 (B)	HOLD	USA
None	Ophthalmology	Eyenovia (EYEN) Apellis (APLS)	18 months	May 7 2025	EPS -0.15 -8% MISS Revenue 7.5M +5% Beat EPS -0.25 +8% Beat Revenue 15.3M +10% Beat	Aug 5 2025 (est.) Aug 5 2025 (est.)	6 (B) 7 (B+)	BUY	USA
None	Oncology	Arvinas (ARVN) Mersana (MRSN)	18 months	May 8 2025	EPS -0.25 +8% Beat Revenue 15.3M +10% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Immunology	KalVista (KALV) CSL Behring	12 months	May 7 2025	EPS -0.65 -12% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	5 (B-)	SELL	USA
Pfizer (PFE)	Oncology	Kura (KURA) Nurix (NRIX)	15 months	May 8 2025	EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Health Insurance	UnitedHealth (UNH) Cigna (CI)	N/A	May 7 2025	EPS 0.15 +12% Beat Revenue 2.1B +10% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Ophthalmology	Ocular (OCUL) Eyenovia (EYEN)	15 months	May 8 2025	EPS -0.15 -8% Miss Revenue 10.2M +5% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Pfizer (PFE)	Oncology	Mersana (MRSN) MacroGenics (MGNX)	N/A	May 7 2025	EPS 0.05 +10% Beat Revenue 45.3M +8% Beat	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Vaccines	Pfizer (PFE) Moderna (MRNA)	24 months	May 8 2025	EPS -0.95 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	8 (A-)	BUY	USA
Merck (MRK)	Oncology	IO Biotech (IOBT) Mersana (MRSN)	15 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
None	Oncology	IO Biotech (IOBT) PDS Biotech (PDSB)	12 months	May 7 2025	EPS -0.10 -10% Miss Revenue 1.2M -5% Miss	Aug 5 2025 (est.)	5 (B-)	SELL	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	18 months	May 8 2025	EPS -0.05 +8% Beat Revenue 75.3M +10% Beat	Aug 6 2025 (est.)		HOLD	Netherlands
None	Gastroenterology	Takeda (TAK) Ironwood (IRWD)	18 months	May 7 2025	EPS -0.65 -8% Miss Revenue 7.5M +12% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	HAE	KalVista (KALV) CSL Behring	20 months	May 8 2025	EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	Netherlands
None	Fibrosis	FibroGen (FGEN) 89bio (ETNB)	18 months	May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY	USA
None	Regenerative Medicine	Celularity (CELU) Mesoblast (MESO)	12 months	May 8 2025	EPS -0.25 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	5 (B-)	SELL	Israel
None	Gene Editing	Intellia (NTLA) Editas (EDIT)	15 months	May 7 2025	EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	6 (B)	HOLD	USA
BMS (BMY)	Neurodegenerative Diseases	Denali (DNLI) Alector (ALEC)	18 months	May 8 2025	EPS -0.95 -8% Miss Revenue 2.3M -5% Miss	Aug 6 2025 (est.)	6 (B)	BUY	USA
None	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	N/A	May 7 2025	EPS -1.25 -10% Miss Revenue 175.4M +8% Beat	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Takeda (TAK)	Hematology	Keros (KROS) Geron (GERN)	20 months	May 8 2025	EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	7 (B+)	BUY	USA
CSL Behring	Gene Therapy	Krystal (KTTA) 4DMT (FDMT)	15 months	May 7 2025	EPS -1.15 -12% Miss Revenue 2.5M -5% Miss	Aug 5 2025 (est.)	6 (B)	HOLD	Netherlands
Mereo (MREO)	Rare Diseases	Amicus (FOLD) BioMarin (BMRN)	N/A	May 8 2025	EPS -1.85 -8% Miss Revenue 125.3M +10% Beat	Aug 6 2025 (est.)	8 (A-)	BUY	USA
None	Gene Therapy	uniQure (QURE) Krystal (KTTA)	20 months	May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 5 2025 (est.)	7 (B+)	BUY	USA
Gilead (GILD) Taiho Oncology	Oncology	Amgen (AMGN) Merck (MRK)	18 months	May 8 2025	EPS -0.95 -8% Miss Revenue 45.2M +12% Beat	Aug 6 2025 (est.)	6 (B)	HOLD	USA
Sanofi (SNY) Bayer	Ophthalmology Immunology	Amgen (AMGN) Roche (RHHBY)	N/A	May 7 2025	EPS 10.25 +15% Beat Revenue 3.2B +10% Beat	Aug 5 2025 (est.)	9 (A)	STRONG BUY	USA
Regeneron (REGN)	Oncology	IO Biotech (IOBT) PDS Biotech (PDSB)	15 months	May 8 2025	EPS -0.85 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.)	6 (B)	HOLD	USA
None	Gene Therapy	uniQure (QURE) Rocket (RCKT)	18 months	May 7 2025	EPS -1.25 -8% Miss Revenue 15.3M -5% Miss	Λ Γ 000Γ (+)	C (D)	HOLD	USA
None	Hematology	Geron (GERN) Jazz (JAZZ)	18 months	May 8 2025		Aug 5 2025 (est.)	6 (B)	HOLD	1
None	Oncology	Nuvelent (NU IVI) Kura (KUDA)			EPS -0.05 +8% Beat Revenue 36.4M +10% Beat	Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B)		USA
BMS (BMY)		Nuvalent (NUVL) Kura (KURA)	15 months	May 7 2025	EPS -0.05 +8% Beat Revenue 36.4M +10% Beat EPS -0.75 -10% Miss Revenue 0.0M N/A	. ,		HOLD	USA
Pfizer (PFE) Merck (MRK)	Rare Diseases	Amicus (FOLD) Ultragenyx (RARE)	15 months 20 months	-		Aug 6 2025 (est.)	6 (B)	HOLD BUY	
	Rare Diseases Royalty Financing			May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B)		USA
None		Amicus (FOLD) Ultragenyx (RARE)	20 months	May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+)	BUY	USA USA
None	Royalty Financing	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO)	20 months N/A	May 7 2025 May 8 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8%	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+)	BUY BUY	USA USA USA
	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL)	20 months N/A 24 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-)	BUY BUY HOLD BUY	USA USA USA USA USA
None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN)	20 months N/A 24 months 18 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B)	BUY BUY HOLD BUY HOLD	USA USA USA USA USA USA USA
None None Biogen (BIIB)	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM)	20 months N/A 24 months 18 months 24 months 15 months 18 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B)	BUY BUY HOLD BUY HOLD HOLD	USA USA USA USA USA USA USA USA
None None Biogen (BIIB) None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B)	BUY BUY HOLD BUY HOLD HOLD HOLD	USA
None None Siogen (BIIB) None Pfizer (PFE)	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT)	20 months N/A 24 months 18 months 24 months 15 months 18 months 10 months 20 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025 May 8 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 7 2025 (est.) Aug 7 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 5 (B-	BUY BUY HOLD BUY HOLD HOLD HOLD SELL	USA
None None None Biogen (BIIB) None Pfizer (PFE) None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT)	20 months N/A 24 months 18 months 24 months 15 months 18 months 10 months 12 months 18 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 7 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B)	BUY BUY HOLD BUY HOLD HOLD HOLD HOLD HOLD	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 7 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc.	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 7 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUL HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology Allergy	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 18 months 18 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUY HOLD BUY BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 24 months 25 months 26 months 27 months 28 months 29 months 20 months 20 months	May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Beat Revenue 0.0M N/A EPS -0.55 +8% Beat Revenue 0.0M N/A EPS -0.55 -8% Miss Revenue 0.0M N/A EPS -0.55 -10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 6 2025 (est.) Aug 7 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUY BUY BUY BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 24 months 20 months 18 months 20 months 18 months 18 months	May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUY HOLD BUY HOLD BUY HOLD BUY BUY BUY HOLD	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None None Akeso Inc. None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 24 months 20 months 18 months 20 months 18 months 18 months 18 months 18 months	May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 6 (B)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY HOLD HOLD HOLD BUY BUY BUY BUY HOLD HOLD	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None None Akeso Inc. None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 24 months 20 months 18 months 21 months 18 months 18 months 18 months 18 months 18 months 18 months	May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 8 (A-)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY HOLD HOLD BUY BUY BUY BUY BUY BUY BUY BUY BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 20 months 18 months 18 months 18 months 18 months 19 months 10 months 110 months 1110 months 112 months 112 months	May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 6 (B) 5 (B-)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY HOLD BUY HOLD BUY BUY BUY BUY BUY BUY BUY SELL	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 20 months 18 months 18 months 18 months 18 months 19 months 10 months 110 months 110 months 1110 months 1110 months 1110 months 1110 months 1110 months	May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025 May 7 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.85 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 6 (B)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY HOLD BUY BUY BUY BUY BUY BUY BUY HOLD HOLD HOLD	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Immunology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 21 months 18 months 19 months 10 months 110 months 1110 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.55 +8% Beat Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.85 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Immunology Oncology Oncology Oncology Obesity	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 21 months 18 months 20 months 18 months 18 months 19 months 10 months 110 months 1110 months 112 months 112 months 113 months 113 months 114 months 115 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 6 (B) 7 (B+) 7 (B+) 7 (B+) 8 (A-) 5 (B-) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Immunology Oncology Immunology Obesity Immunology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 21 months 18 months 20 months 18 months 18 months 20 months 18 months 20 months 18 months 18 months 15 months 15 months 15 months 15 months 15 months 15 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.55 +8% Beat Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Chesity Immunology Respiratory	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 20 months 18 months 18 months 20 months 18 months 20 months 18 months 20 months 18 months 15 months 15 months 15 months 15 months 24 months 24 months 25 months 26 months 27 months 28 months 29 months 20 months 20 months 20 months 21 months 22 months 23 months 24 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD SELL HOLD BUY BUY BUY BUY BUY BUY HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Immunology Oncology Immunology Obesity Immunology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 21 months 18 months 20 months 18 months 18 months 20 months 18 months 20 months 18 months 18 months 15 months 15 months 15 months 15 months 15 months 15 months	May 7 2025 May 8 2025 2025 May 7 2025 May 8 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.55 +8% Beat Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 7 (B+) 6 (B) 8 (A-) 5 (B-) 6 (B) 7 (B+) 7 (B+) 6 (B)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Immunology Oncology Immunology Oncology Respiratory Oncology Oncology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 12 months 18 months 20 months 18 months 15 months 15 months 15 months 20 months 15 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 28.4M +10% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Oncology Respiratory Oncology Neurodegenerative Diseases	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 18 months 24 months 20 months 18 months 20 months 18 months 20 months 18 months 20 months 18 months 21 months 18 months 15 months 15 months 15 months 15 months 20 months 15 months 15 months 15 months 15 months 16 months 17 months 18 months 18 months 18 months 18 months 18 months 18 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Chesity Immunology Respiratory Oncology Neurodegenerative Diseases Rare Diseases	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC) Amicus (FOLD) Ultragenyx (RARE)	20 months N/A 24 months 18 months 24 months 15 months 18 months 10 months 11 months 12 months 13 months 14 months 15 months 16 months 17 months 18 months 18 months 19 months 19 months 10 months 11 months 11 months 11 months 12 months 13 months 14 months 15 months 15 months 16 months 17 months 18 months	May 7 2025 May 8 2025 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.85 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 5 (B-) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY BUY BUY BUY BUY BUY BUY BUY BUY HOLD HOLD BUY SELL HOLD HOLD HOLD BUY SELL HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Oncology Respiratory Oncology Neurodegenerative Diseases Rare Diseases CNS Disorders	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC) Amicus (FOLD) Ultragenyx (RARE) Sage (SAGE) Jazz (JAZZ)	20 months N/A 24 months 18 months 24 months 15 months 18 months 10 months 11 months 12 months 13 months 14 months 15 months 16 months 17 months 18 months 18 months 19 months 19 months 10 months 11 months 11 months 11 months 12 months 13 months 14 months 15 months 15 months 16 months 17 months 18 months 18 months 18 months 18 months 19 months 19 months 10 months 10 months 11 months 11 months 12 months 12 months 13 months 14 months 15 months	May 7 2025 May 8 2025 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.55 +8% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY BUY BUY BUY BUY BUY BUY HOLD HOLD BUY BUY HOLD HOLD BUY SELL HOLD HOLD BUY SELL HOLD BUY SELL HOLD BUY SELL HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Oncology Respiratory Oncology Neurodegenerative Diseases Rare Diseases CNS Disorders	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC) Amicus (FOLD) Ultragenyx (RARE) Sage (SAGE) Jazz (JAZZ) MannKind (MNKD) Corcept (CORT)	20 months N/A 24 months 18 months 24 months 15 months 18 months 10 months 11 months 12 months 13 months 14 months 15 months 16 months 17 months 18 months 18 months 18 months 19 months 19 months 10 months 11 months 11 months 11 months 12 months 13 months 14 months 15 months 15 months 16 months 17 months 18 months 18 months 18 months 19 months 19 months 19 months 10 months 10 months 11 months 12 months 13 months 14 months 15 months 15 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Oncology Respiratory Oncology Neurodegenerative Diseases Rare Disorders Endocrinology Oncology Oncology Oncology Oncology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC) Amicus (FOLD) Ultragenyx (RARE) Sage (SAGE) Jazz (JAZZ) MannKind (MNKD) Corcept (CORT) Pfizer (PFE) Kura (KURA)	20 months N/A 24 months 18 months 24 months 15 months 18 months 10 months 11 months 12 months 13 months 14 months 15 months 16 months 17 months 18 months 18 months 19 months 19 months 10 months 11 months 11 months 11 months 12 months 13 months 14 months 15 months 15 months 16 months 17 months 18 months 18 months 19 months 19 months 19 months 10 months 11 months 11 months 12 months 13 months 14 months 15 months 15 months 16 months 17 months 18 months 18 months 18 months 18 months	May 7 2025 May 8 2025 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +89 EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY BUY BUY BUY BUY BUY BUY BUY HOLD HOLD BUY SELL HOLD HOLD BUY SUY BUY BUY BUY BUY BUY BUY BUY BUY BUY B	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Oncology Respiratory Oncology Neurodegenerative Diseases Rare Disorders Endocrinology Oncology Oncology Oncology Oncology	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC) Amicus (FOLD) Ultragenyx (RARE) Sage (SAGE) Jazz (JAZZ) MannKind (MNKD) Corcept (CORT) Pfizer (PFE) Kura (KURA) Kura (KURA) Relay (RLAY)	20 months N/A 24 months 18 months 24 months 15 months 18 months 20 months 18 months 24 months 20 months 18 months 15 months 15 months 15 months 15 months 24 months 24 months 24 months 25 months 26 months 27 months 28 months 29 months 29 months 20 months 20 months 20 months 21 months 22 months 23 months 24 months 25 months 26 months 27 months 28 months 29 months 20 months 20 months 21 months 22 months 23 months 24 months 24 months 25 months 26 months 27 months 28 months 29 months 20 months 20 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 28.4M +10% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -1.65 -8% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.45 -10% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.55 -8% Miss Revenue 0.0M N/A EPS -0.55 -8% Miss Revenue 0.0M N/A EPS -0.55 -10% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD SELL HOLD BUY BUY BUY BUY BUY BUY BUY BUY HOLD HOLD BUY SELL HOLD BUY SELL HOLD HOLD BUY SELL	USA
None None None Biogen (BIIB) None Pfizer (PFE) None None Akeso Inc. None None None None None None None None	Royalty Financing Oncology Al-Driven Drug Discovery Rare Diseases Rare Diseases CNS Disorders Cell Therapy Gene Therapy Rare Diseases Oncology Allergy CNS Disorders Immunology Cell Therapy Immunology Oncology Oncology Immunology Obesity Immunology Respiratory Oncology Neurodegenerative Diseases Rare Diseases CNS Disorders Endocrinology Oncology Oncology Respiratory Oncology Neurodegenerative Diseases Rare Diseases Endocrinology Oncology Royalty Financing	Amicus (FOLD) Ultragenyx (RARE) Ligand (LGND) Halozyme (HALO) Kura (KURA) Nuvalent (NUVL) Exscientia (EXAI) Absci (ABSI) Amicus (FOLD) Ultragenyx (RARE) Amicus (FOLD) BioMarin (BMRN) Jazz (JAZZ) Axsome (AXSM) Allogene (ALLO) Lyell (LYEL) uniQure (QURE) Rocket (RCKT) Ultragenyx (RARE) Rocket (RCKT) Rhythm (RYTM) Amicus (FOLD) Amgen (AMGN) Merck (MRK) KalVista (KALV) CSL Behring Sage (SAGE) Jazz (JAZZ) Regeneron (REGN) AnaptysBio (ANAB) Lyell (LYEL) Allogene (ALLO) Argenx (ARGX) Regeneron (REGN) Kura (KURA) Nuvalent (NUVL) Relay (RLAY) Nuvalent (NUVL) Argenx (ARGX) Regeneron (REGN) Novo Nordisk (NVO) Eli Lilly (LLY) Argenx (ARGX) Regeneron (REGN) Insmed (INSM) Chiesi Kura (KURA) Relay (RLAY) Denali (DNLI) Alector (ALEC) Amicus (FOLD) Ultragenyx (RARE) Sage (SAGE) Jazz (JAZZ) MannKind (MNKD) Corcept (CORT) Pfizer (PFE) Kura (KURA) Kura (KURA) Relay (RLAY) Ligand (LGND) Royalty Pharma (RPRX)	20 months N/A 24 months 18 months 24 months 15 months 18 months 12 months 18 months 20 months 18 months 15 months 15 months 15 months 15 months 15 months 24 months 24 months 24 months 15 months 24 months 15 months 17 months 18 months 18 months 19 months 19 months 10 months 110 months 1110 months 112 months 113 months 114 months 115 months	May 7 2025 May 8 2025 May 8 2025 May 7 2025 May 8 2025 May 7 2025 May 7 2025 May 8 2025	EPS -0.75 -10% Miss Revenue 0.0M N/A EPS -0.65 -8% Miss Revenue 10.5M +5% Beat EPS 0.95 +12% Beat Revenue 650.3M招待所M +8% EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.45 -8% Miss Revenue 15.2M +5% Beat EPS -0.75 +8% Beat Revenue 28.4M +10% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.35 -10% Miss Revenue 12.3M +5% Beat EPS -0.35 -10% Miss Revenue 0.0M N/A EPS -0.15 -0% Miss Revenue 0.0M N/A EPS -0.65 -10% Miss Revenue 0.0M N/A EPS -0.25 +8% Beat Revenue 0.0M N/A EPS -0.05 -8% Miss Revenue 0.0M N/A EPS -0.15 +10% Beat Revenue 5.3M +12% Beat EPS -0.55 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.35 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 0.0M N/A EPS -0.25 -8% Miss Revenue 0.0M N/A EPS -0.25 -10% Miss Revenue 45.3M +5% Beat EPS -0.25 -10% Miss Revenue 45.3M +12% Beat EPS -0.85 -10% Miss Revenue 0.0M N/A EPS -0.35 -12% Miss Revenue 0.0M N/A EPS -0.35 -12% Miss Revenue 0.0M N/A	Aug 6 2025 (est.) Aug 5 2025 (est.) Aug 6 2025 (est.)	6 (B) 6 (B) 7 (B+) 8 (A-) 7 (B+) 6 (B) 8 (A-) 6 (B) 6 (B) 6 (B) 5 (B- 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 6 (B) 7 (B+) 7 (B+) 7 (B+) 6 (B) 7 (B+)	BUY BUY HOLD BUY HOLD HOLD HOLD BUY	USA

Comments	
Trading below cash value; strong partnerships; pipeline advancing but revenue growth limited[](https://x.com/Hedgebullish/status/1932116713451209027)[](https://x.com/brooks_david3/status/193046157895810))6742)[](<u>htt</u>
Limited revenue; cash runway constrained; EB-101 pivotal data critical Al-driven platform gaining traction; early-stage pipeline; partnerships strong	
HBV focus; limited near-term catalysts; cash runway tight	
Strong commercial traction with DAYBUE; pipeline expansion promising High-risk cell therapy; limited cash runway; early-stage pipeline	
Promising cell therapy pipeline; strong partnership with Gilead Small-cap dermatology focus; limited cash runway; pipeline early-stage	
High-risk T-cell therapy; cash runway constrained; GSK partnership key	
clonoSEQ commercialized; diagnostic focus; stable but slow growth Strong commercial growth; expanding manufacturing capacity; financially stable	
High-risk immuno-oncology; cash runway tight; pipeline speculative	
PYRUKYND commercialized; pipeline advancing; stable cash position Ophthalmology focus; reproxalap pivotal data key; cash runway limited	
Neuro focus; GSK partnership; early-stage pipeline Allogeneic cell therapy; high-risk; Pfizer partnership key	
Strong RNAi portfolio; multiple approved drugs; robust pipeline[](https://www.biopharmcatalyst.com/news/2020/argenx-argx-shares-rally-on-positive-late-stage-data-34-alnylam-alny-lumasiran-pdufa-set-for-dec	ember)
Stable generics business; limited innovation; financially sound NASH focus; EFX pivotal data critical; strong cash position	
Immunology pipeline; GSK partnership; moderate risk	
High-risk neuro focus; limited cash runway; early-stage pipeline[](https://finance.yahoo.com/quote/ANVS/) Strong commercial traction with SYOVRE; pipeline expanding	
RNAi focus; early-stage pipeline; moderate risk Strong commercial growth; IBSRELA sales ramping; stable finances[](https://www.biopharmcatalyst.com/company/ARDX)	
VYVGART strong commercial success; robust pipeline; financially stable[](https://www.biopharmcatalyst.com/news/2020/argenx-argx-shares-rally-on-positive-late-stage-data-34-alnylam-alny-lumasiran-pdufa-se	et-for-dece
Small-cap bacteriophage focus; limited cash runway; high-risk pipeline ZORYVE commercial traction; expanding indications; stable finances[](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/valuation)	
PROTAC platform innovative; early-stage pipeline; Pfizer partnership key	
HBV focus; limited cash runway; high-risk early-stage pipeline Strong commercial portfolio; TransCon platform promising; financially stable	
High-risk neuro focus; limited cash runway; pivotal data critical Early-stage HAE focus; moderate risk; cash runway sufficient	
Small-cap pulmonary focus; limited cash runway; high-risk pipeline	
Ocular oncology niche; early-stage pipeline; moderate risk LUPKYNIS commercial success; stable finances; expanding indications	
Antiviral focus; early-stage pipeline; Roche partnership key	
Neuro focus; high-risk pipeline; pivotal data critical Strong commercial traction; AUVELITY sales growing; robust pipeline	
Promising cardiomyopathy pipeline; strong partnerships; stable finances Early-stage oncology focus; moderate risk; cash runway sufficient	
ORLADEYO commercial success; pipeline advancing; stable finances	
Gene editing platform; early-stage pipeline; strong partnerships Established neuro portfolio; LEQEMBI sales growing; financially stable	
APHEXDA recently approved; commercial ramp-up critical; limited cash runway[](https://www.nasdaq.com/articles/jnj-acquires-mnta-fda-strikes-down-bmrns-gene-therapy-blrxs-genesis-on-track-tptx-on-watch)
Oncology focus; early-stage pipeline; moderate risk Strong rare disease portfolio; VOXZOGO sales robust; financially stable[](https://www.nasdaq.com/articles/jnj-acquires-mnta-fda-strikes-down-bmrns-gene-therapy-blrxs-genesis-on-track-tptx-on-watch)	
COMIRNATY global success; mRNA oncology pipeline promising; financially stable Precision oncology leader; AYVAKIT sales growing; strong pipeline	
IGALMI approved but limited uptake; high-risk pipeline; cash runway constrained	
Oncology focus; early-stage pipeline; limited cash runway Small-cap oncology; high-risk pipeline; cash runway constrained	
Cardiomyopathy focus; early-stage pipeline; partnership with Nippon Shinyaku Oncology focus; early-stage pipeline; moderate risk	
High-risk cell therapy; limited cash runway; early-stage pipeline	
Pre-clinical regenerative medicine; high-risk; limited cash runway Promising immunology pipeline; barzolvolimab data key; stable finances[](https://finance.yahoo.com/quote/CLDX/)	
Oncology focus; early-stage pipeline; Taiho partnership	
Bladder cancer focus; promising phase 3 data; stable cash position High-risk neuro focus; limited cash runway; early-stage pipeline	
UDENYCA commercialized; biosimilar focus; moderate growth High-risk oncology; limited cash runway; pivotal data critical	
Ophthalmology focus; early-stage pipeline; cash runway constrained[](https://finance.yahoo.com/quote/CRVS/) High-risk cell therapy; limited cash runway; early-stage pipeline[](https://finance.yahoo.com/quote/CLLS/)	
Oncology focus; early-stage pipeline; cash runway limited	
Hemophilia focus; promising pipeline; stable cash position Oncology focus; early-stage pipeline; moderate risk	
Neuro focus; early-stage pipeline; moderate cash runway	
KORLYM strong commercial performance; pipeline advancing; financially stable Strong commercial growth with FIRDAPSE; AGAMREE sales ramping; financially stable[](https://stockanalysis.com/stocks/cprx/)	
Oncology focus; early-stage pipeline; promising data High-risk oncology; limited cash runway; early-stage pipeline	
DEFENCATH recently approved; commercial ramp-up critical; moderate cash runway	
DEFENCATH recently approved; commercial ramp-up critical; moderate cash runway Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited [[(https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b)	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited][(https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolio; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; stable cash position	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited[](https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolio; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited[[https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolio; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; stable cash position Antiviral focus; early-stage pipeline; moderate cash runway Jeuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; Janssen partnership	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited[[(https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolio; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; stable cash position Antiviral focus; early-stage pipeline; moderate cash runway Jeuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; Janssen partnership Oncology focus; naporafenib pivotal data key; Novartis partnership NSH focus; promising phase 2 data; stable cash position	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited][https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolio; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; stable cash position Antiviral focus; early-stage pipeline; moderate cash runway Jeuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; Janssen partnership Oncology focus; early-stage pipeline; Janssen partnership	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojenda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline Neuro focus; strong partnerships; promising pipeline Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited [https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolic; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; stable cash position Antiviral focus; early-stage pipeline; moderate cash runway Jeuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; Janssen partnership NASH focus; promising phase 2 data; stable cash position Al-driven platform; early-stage pipeline; strong partnerships Cabometyx strong commercial performance; robust pipeline Mydcombi approved; commercial performance; robust pipeline	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited [[https://ir.editasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolic; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline; astable cash position Antiviral focus; early-stage pipeline; moderate cash runway Jeuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; moderate cash runway Antiviral focus; early-stage pipeline; yanssen partnership Oncology focus; naporafenib pivotal data key; Novartis partnership NASH focus; promising phase 2 data; stable cash position Al-driven platform; early-stage pipeline; strong partnerships Cabometyx strong commercial performance; robust pipeline	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Aficamten pivotal data critical; strong cash position; commercial potential Ojernda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline Neuro focus; strong partnerships; promising pipeline EPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; ash runway limited[[https://i.ceditasmedicine.com/static-files/b6d9235d-41cc-4266-8526-b5d8618c431b) Strong animal health portfolic; recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; stable cash position Antiviral focus; early-stage pipeline; stable cash position Oncology focus; early-stage pipeline; moderate cash runway Jeuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; Janssen partnership Oncology focus; pomising phase 2 data; stable cash position Al-driven platform; early-stage pipeline; stong partnerships Cabometyx strong commercial performance; robust pipeline Mydcombi approved; commercial ramp-up critical; limited cash runway	
Endocrinology focus; parlusotine pivotal data key; stable cash position Casgavy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Alicamten pivotal data critical; strong cash position; commercial potential Ojemda recently approved; pediatric focus; stable cash runway Neuro focus; strong partnerships; promising pipeline HEPLISA/LB strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway limited[https://i.cditasmedicine.com/static-files/b5d9235d-41cc-4266-8526-b5d8618431b) Strong animal health portfolic, recent product approvals; financially stable High-risk oncology; limited cash runway; early-stage pipeline; table runway; early-stage pipeline; moderate cash runway Antiviral focus; early-stage pipeline; moderate cash runway Leuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; moderate cash runway Leuveau strong aesthetics market performance; expanding indications Oncology focus; early-stage pipeline; strong partnership Casomety, strong commercial performance; expanding indications Oncology focus; early-stage pipeline; strong partnership Cadomety, strong commercial performance; robust pipeline Al-driven platform: early-stage pipeline; strong partnerships Cadomety, strong commercial performance; robust pipeline Mydornibi approved; commercial ramp-up critical; limited cash runway VUTIQ commercial;erce; EYP-1901 data key; moderate cash runway Figh-risk fibrosis focus; limited cash runway; pivotal data critical Strong rare diesese portfolic, Galafold sales robust; financially stable CRO services stable; strong client base; financially stable	
Endocrinology focus; paltusotine pivotal data key; stable cash position Casgevy approved; strong Vertex partnership; expanding pipeline Oncology focus; early-stage pipeline; Amgen partnership key Alicamten pivotal data critical; strong cash position; commercial potential Oncology focus; early-stage pipeline; Amgen partnerships promising pipeline Neuro focus; strong partnerships; promising pipeline Neuro focus; strong partnerships; promising pipeline NEPLISAV-B strong commercial performance; stable finances Gene editing focus; early-stage pipeline; cash runway imitedlibitiss//iceditasmedicine.com/static-files/b5d9235d-41co-4266-8526-b5d8618c431b) Strong animal health portfolic, recent product approvals; financially stable Strong animal health portfolic, recent product approvals; financially stable Oncology focus; early-stage pipeline; stable cash position Al-driven platform; early-stage pipeline; strong partnership Oncology focus; early-stage pipeline; strong partnership Oncology focus; early-stage pipeline; strong partnership Oncology focus; early-stage pipeline; strong partnership Al-driven platform; early-stage pipeline; strong partnership Uniform platform; early-stage pipeline; strong partnership Oncology focus; early-stage pipeline; strong partnership Cabometys strong commercial partormance; robust pipeline Mydombil approved; commercial partormance; robust pipeline Cabometys strong commercial partormance; robust pipeline Cabometys strong commercial partormance; robust pipeline Cabometys strong commercial partormance; robust pipeline cabo each nunway Uniform commercial partormance; robust pipeline cabo each nunway Oncology focus; early-stage pipeline; strong partnerships Cabometys strong commercial partormance;	
Endocrinology focus; partusoitine pivotal data key; stable cash position Casgavy approved; strong Vertox partinership; expanding pipeline Ancenters proved data critical; strong cash position; commercial potential Openda recently approved; pediatric focus; stable cash runway Nauro focus; strong partnerships; promising pipeline REPUSAVB attrong commercial performance; stable frances Gene editing focus; early-stage pipeline; variety pipeline REPUSAVB attrong commercial performance; stable frances Gene editing focus; early-stage pipeline; cash runway intritedfilatrics//reditamedicine.com/static-files/b58295d-41cc-4268-8598-b5868186431b) Strong animal health portfolic; recent product approvals; francially stable High-risk nocology; limited cash runway, early-stage pipeline Cocology focus; early-stage pipeline; stable cash position Antiviral focus; early-stage pipeline; moderate cash runway Ancelogy focus; early-stage pipeline; moderate cash runway Ancelogy focus; early-stage pipeline; moderate cash runway Ancelogy focus; early-stage pipeline; strong partnership Cocology focus; early-stage pipeline; strong partnership Ancelogy focus; early-stage pipeline; strong partnerships Ancelogy focus; early-stag	
Endocrinationly focus; pull-usorbine private data keys stable cash position Casagevy approved; strong ketner partnership; sepanding pipeline Afcammen private data critical; stong cash position; commercial potential Opmota recently approved; peripikin, kringen parlmership key Afcammen private data critical; stong cash position; commercial potential Opmota recently approved; peripiking pipeline Neuro focus; strong partnerships; promising pipeline Neuro focus; strong partnerships; promising pipeline Neuro focus; strong partnerships; promising pipeline PEPUSAV9 8 trong commercial performance; stotel finances Gene editing focus; early-stage pipeline; cash runway limited jilittps://in-editasmedicine.com/statio-files/b5d9235d-41cc-4266-8526-b56818431b) Strong animal health portfolic; recent product approvals; financially stablo Strong animal health portfolic; recent product approvals; financially stablo Allorises consistent of the product approvals; financially stablo Oncology focus; carry-stage pipeline; stable cash position Antivari focus; early-stage pipeline; stable cash position Antivari focus; promising phase 2 data; stable cash position Antivari focus; promising phase 2 data; stable cash position Antivari for formancial performance; robust pipeline Antivari for formance; and performance; robust pipeline Antivari for formance; pipeline; stable cash position Antivari for data and performan	
Endocrinality floaus; parturatine pivotal data key; stable cash position Caspey approved; strong Vartex partnership; expanding pipeline Oncology floaus; early-stage pipeline; Angen partnership korn Alexander provaid data critical; strong cash position; commercial potential Ojenda recently approved; pediatric floaus; stable cash runway Neuro facus; strong partnerships; promising pipeline FEPLSAVB strong commercial performance; stable finances Gene editing floaus; early-stage pipeline; cash runway intribud[https://ip.edilasmedicine.com/static-files/b5d9235d-t1c-d286-8826-b5d8818c431b) Strong animal health portfolic; recent product approvals; financially stable High-risk nocology, limited dash runway, early-stage pipeline Cocology floaus; early-stage pipeline; stable cash position Antiviral floaus; early-stage pipeline; moderate cash runway Jeuveau strong ausshedos market performance; expanding indications Oncology floaus; early-stage pipeline; stable cash position Antiviral floaus; early-stage pipeline; strong partnership Oncology floaus; early-stage pipeline; strong partnership Oncology floaus; early-stage pipeline; strong partnership Oncology floaus; early-stage pipeline; strong partnership Additional partnership promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase 2 data; stable cash position All floaus; promising phase	
Enclosinatory focus: parturactine photal data key; stable cash position Coscopy founs, entr-stage poelines, Amone partenish pice yearding piceline Coccopy focus, entr-stage poelines, Amone partenish piceline Commercial partenish protein data critical; strong cash position; commercial potential Cyenda resembly approved; celestric focus; stable cash runway Neutro focus; strong parturariships; positions; cush runway Neutro focus; strong parturariships; positions; cush runway introductions (strong commercial performance; stable finances Gene outling focus; early-stage pipeline; cush runway introductions (strong provide; transicially stable) HEPLISAV-8 strong commercial performance; stable finances Gene outling focus; early-stage pipeline; cush runway introductions (strong provide; transicially stable) High-risk discoology; limited cush runway; early-stage pipeline; cush runway; early-stage pipeline; cush runway; early-stage pipeline; moderate cash runway Activatal focus; early-stage pipeline; moderate cash runway Activatal focus; early-stage pipeline; moderate cash runway Activatal postus; early-stage pipeline; moderate cash runway Activatal focus; early-stage pipeline; moderate cash runway Activatal postus; early-stage pipeline; strong partenesing Activatal postus; early-stage pipeline; strong partenesing Activates a strong commercial performance; robust pipeline Activates a strong commercial performance; robust pipeline Activates pipeline; strong cardiac strong partenesing Activates focus; strong commercial performance; robust pipeline Activates focus; strong commercial per	
Endocrinology facus; pathwacine photal data key, stable cash position Casgavy approved; strong Werker partnership, expanding pipeline Concology facus; early-stage pipeline; Ampe partnership key Afcamten pixelic data critical, strong cash position: commercial potential Opendar centrity approved; pediatric facus; stable cash runway Neuro facus; strong partnerships; promising pipeline HEPUSAVB strong commercial partnermance; stable framea Rear editing facus; early-stage pipeline; cash runway limited[limps://ir.editasmedicine.com/static-files/b5d9255d-11c-4268-8526-b5d8818431b) Strong animal health portfolic; recent product approvals; financially stable Playin-final concology intendic stah runway limited glimps://ir.editasmedicine.com/static-files/b5d9255d-11c-4268-8526-b5d8818431b) Strong animal health portfolic; recent product approvals; financially stable Playin-final concology intendic stah runway limited glimps://ir.editasmedicine.com/static-files/b5d9255d-11c-4268-8526-b5d8818431b) Strong playin-final cash runway limited glimps://ir.editasmedicine.com/static-files/b5d925d-11c-4268-8526-b5d8818431b) Strong playin-final cash runway limited glimps://ir.editasmedicine.com/static-files/b5d925d-11c-4268-8526-b5d8818431b) Strong playin-final cash runway playin-final files/b5d925d-11c-4268-8526-b5d8818431b) Strong playin-final cash runway playin-final files/b5d925d-11c-4268-8526-b5d8818431b) Strong playin-final files/b5d925d-11c-4268-8526-b5d8818431b) Strong playin-final files/b5d925d-11c-4268-8526-b5d8818431b) Strong playin-fin	
Endocrinationy focus; partusorine pivotal data key; stable cash position Casagery approved; strong Vertez partnership; separding pipeline Casagery approved; strong Vertez partnership; separding pipeline Clonically stocus; and-stage partnership; separding pipeline Clonically course and partnership; perinding pipeline Neuro trust; strang producting producting coach movely intellultitus/firestitumentation convisitis illus/b50254-14:e-4208-8526-856818-64319 Neuro trust; strang producting producting provisits; financially stable Neuro trust, strang producting producting provisits; financially stable Neuro trust, strang producting producting provisits; financially stable Neuro trust, strang producting cash movely intellultitus/firestitumentation convisitis illus/b50254-14:e-4208-8526-856818-64319 Neuro trust, strang producting cash movely intellultitus/firestitumentation convisitis illus/b502554-14:e-4208-8526-856818-64319 Neuro trust, strang production cash movel, intellultitus/firestitumentation convisitis illus/b502554-14:e-4208-8526-856818-64319 Neuro trust, strang partnership production cash movel, strangilly stable Neuro production production cash trust, strangilly stable Neuroscial production strategy performance, repeated pipeline Neuroscial production strategy performance, reposit specified Neuroscial partnership production data keys hovering partnerships Neuroscial partnership partnerships in stable cash nurway Neuroscial partnership partnerships in stable cash nurway Neuroscial partnership partnerships in stable cash nurway Neuroscial partnership partnershi	
Endocrinology focus; pilutestrie protest data key; stable ceah position Cangery sperowert, strong Warter partnerships; expansing pipeline Concaling funas early signe popeline, replace protessing pipeline Allocarries pional data critical transp cases position; commercial potential Opardia recently approved; pediatric from; sisse position; commercial protestial CPURANE altering commercial performance; stable feath runway INCELINANE altering commercial performance; stable feath runway INCELINANE altering commercial performance; stable frances Gene odring focus; early-stage popeline; control runway inheribipspoint/destanguicine com/state-filian/of/s0/56/4-foc-4/50/-8/50/	
Enclosingly focus: pathsother protat data key; stable cash position Casgery approved: strong briters partnership; expanding poeling Casgery approved: strong briters partnership; expanding poeling Casgery approved: potat critical criti	
Entertive placement potent cata keys stable cath protein Caupeys approved, storing Vertex partherating, coastaring plaetine Coacego's coast, rety stable popeline, framper parametable type Affaunties protein data chilacis strong seath passition commercial potential Coacego's coast, rety stable cate nurses Affaunties protein data chilacis strong seath passition commercial potential Coacego decident potential parametable cate nurses Coacego decident potential parametable cate nurses Coacego decident potential parametable cate nurses proteints Coacego decident potential parametable cate nurses proteints Coacego decident potential parametable stable finances Coacego decident potential potential cates proteints approvised, financially stable Thill-lise Accessories (miles data hurses) architect data fundames and proteints Coacego decident potential data finances Coacego decident data data data data data data data da	
Encoursop frouce, patiented in private data key, about can preading Cangary approved, storny forter partnership, orparating pipeline Cangary approved, storny forter partnership, orparating pipeline Ancenare norther cade critical, storny can position, common partnership key Ancenare norther goods, position forters, store cann runway Candina frouching provincy, position forters, store cann runway Candina frouching provincy, position forters, store cann runway Candina frouching provincy, position forters and cannon private pipeline Cannon dering forters and y storny pipeline cade humany liminod[https://scadesmooline.com/deters/fil/fil/fil/fil/fil/fil/fil/fil/fil/fil	
Exception particular portional data kery stable cash position Costopy focus approved: story Serias partenative particular placetian Costopy focus approved: story Serias partenative particular protection Controlly focus and private particular protection particular protection Controlly focus and private protection provides protection Controlly focus and provides position (and provides particular provides) Controlly focus and provides provides protection provides and unway Neural focus story particularly particularly particularly Controlly focus and provides provides provides and unway Neural focus and provides and unway intellectification and unway intellectification and unway intellectification and unway intellectification and unway and unway intellectification and unway and unway and unway intellectification and unway and unway intellectification and unway and unway and unway intellectification and unway and unway and unway intellectification and unway and unway and unway and unway and unway intellectification and unway	
Reconstruction years (stream, particular) and recitive steep steep recitive steep st	
Endocropy foots; parties after printered is separating pather Casegay stacking through printers printered is separating pather Casegay stacking through pathers printered is separating pather Casegay stacking through pathers printered is separating pather Casegay stacking through pathers printered is separating pathers Casegay stacking stacking pathers printered pathers commenced pathers Casegay stacking stacking pathers printered pathers and pathers Casegay stacking pathers pathers promise a positive First pathers pathers printered pathers are pathers Casegay pathers pathers pathers and pathers Casegay pathers pathers pathers and pathers are pathers Casegay pathers pathers Casegay pathers pathers Casegay Case	
Exception ground, stand, which death death design stands can be possible Caption year, which promoting stands display the Caption (Annual Product Stands Sta	
Educations, Searce patheticists provide data hey seafler calcular groups and considerations and productions and and productions and productions and productions and and productions and and analysis and ana	
Exceptions product product product part of the part or souther Capacity part of the part or souther Capacity part of the part	
Findering for our pullbation profit data large sealer lead position Groups of youthor and profit data large sealer lead position Groups of youth and profit data large sealer lead position Groups of youth and profit data large sealer leads to profit data Groups of youthor and profit data large sealer leads to sealer manage Groups of youthor and youthor profit data large sealer leads to state our manage Groups of youthor youthor profit data large sealer leads to state our manage Groups of youthor youthor profit data large sealer leads to state our manage Groups of youthor youthor profit country management sealer leads on the profit data large sealer leads on the profit data leads on the profi	

High-risk ophthalmology; limited cash runway; pivotal data critical Hematology focus; promising pipeline; stable cash position Oncology focus; ziftomenib data key; moderate cash runway Vyjuvek commercial success; expanding gene therapy pipeline Immunology focus; Sanofi partnership; stable cash position Carvykti strong commercial traction; Janssen partnership; robust pipeline[](https://datafet.com/symbol-list.txt) Ophthalmology focus; early-stage pipeline; moderate cash runway Captisol platform drives revenue; stable royalty stream; financially sound Yutrepia recently approved; commercial ramp-up critical; moderate cash runway Rare disease focus; early-stage pipeline; moderate cash runway Inpefa commercialized; LX9211 data key; moderate cash runway Cell therapy focus; early-stage pipeline; GSK partnership Rezdiffra first-in-class NASH therapy; commercial ramp-up critical; strong cash position[](https://finance.yahoo.com/quote/BBIO/)[](https://www.evaluate.com/node/18476/amp) Cell therapy focus; regulatory hurdles; moderate cash runway[](https://datafet.com/symbol-list.txt) High-risk oncology; limited cash runway; early-stage pipeline[](https://datafet.com/symbol-list.txt) Gene therapy focus; Janssen partnership; moderate cash runway High-risk gene editing; limited cash runway; early-stage pipeline Livmarli commercial success; volixibat data key; stable finances Hypertension focus; early-stage pipeline; moderate cash runway Afrezza commercialized; expanding indications; financially stable[](https://db.cs.cmu.edu/files/data/stocks/history.txt) Psychedelic therapy focus; early-stage pipeline; high-risk high-reward Rare disease focus; setrusumab pivotal data key; Ultragenyx partnership[](https://investorshub.advfn.com/Biotech-Values-1418) Ztalmy commercialized; high-risk pipeline; limited cash runway[](https://finance.yahoo.com/quote/BTAI/)[](https://github.com/pthoang/TDT4310_project/blob/master/FinNum_training_rebuilded.csv) Oncology focus; early-stage pipeline; Janssen partnership[](https://finance.yahoo.com/quote/BTAI/) Oncology focus; zenocutuzumab promising; stable cash position High-risk oncology; limited cash runway; early-stage pipeline[](https://github.com/pthoang/TDT4310_project/blob/master/FinNum_training_rebuilded.csv) Cardiovascular focus; obicetrapib pivotal data key; stable cash position Proteomics platform; pre-clinical stage; moderate cash runway Oncology focus; NBTXR3 pivotal data key; moderate cash runway[](https://finance.yahoo.com/quote/NBTX/?ltr=1) Oncology focus; early-stage pipeline; strong partnerships Gene editing focus; NTLA-2001 promising; Regeneron partnership Oncology focus; early-stage pipeline; moderate cash runway Oncology focus; promising pipeline; strong cash position Ozempic and Wegovy market leaders; robust pipeline; financially stable[](https://finance.yahoo.com/quote/NVO/) Antibody platform; early-stage partnerships; moderate cash runway Dextenza commercialized; AXPAXLI data key; moderate cash runway Oncology focus; early-stage pipeline; moderate cash runway High-risk immunology; limited cash runway; regulatory hurdles Oncology focus; early-stage pipeline; Pfizer partnership[](https://finance.yahoo.com/quote/NBTX/?ltr=1) Health insurance focus; strong growth; not a traditional biotech Upneeq commercialized; niche ophthalmology market; moderate cash runway Nerlynx commercialized; limited growth potential; stable finances Vaccine focus; VAX-24 promising; strong cash position Oncology focus; early-stage pipeline; Merck partnership[](https://investorshub.advfn.com/Biotech-Values-1418) High-risk oncology; limited cash runway; early-stage pipeline Joenja commercialized; rare disease focus; moderate cash runway Voquezna recently approved; commercial ramp-up critical; moderate cash runway HAE focus; deucrictibant pivotal data key; stable cash position Fibrosis focus; bexotegrast promising; stable cash position[](https://finance.yahoo.com/quote/RNA/) High-risk regenerative medicine; limited cash runway; early-stage pipeline Gene editing focus; early-stage pipeline; moderate cash runway Neuro focus; PRX012 promising; BMS partnership Emflaza commercialized; Upstaza US approval pending; stable finances Hematology focus; rusfertide pivotal data key; stable cash position Gene therapy focus; AMT-130 data key; CSL partnership Strong rare disease portfolio; multiple approved drugs; financially stable Gene therapy focus; RP-L201 promising; stable cash position[](https://investorshub.advfn.com/Biotech-Values-1418) Oncology focus; Gilead partnership; moderate cash runway Eylea and Dupixent market leaders; robust pipeline; financially stable[](https://bullishbears.com/biotech-stocks-list/) Oncology focus; early-stage pipeline; Regeneron partnership Gene therapy focus; RGX-121 data key; moderate cash runway Rezlidhia commercialized; niche hematology market; moderate cash runway Oncology focus; early-stage pipeline; moderate cash runway Rare disease focus; AOC 1001 promising; stable cash position[](https://finance.yahoo.com/quote/RNA/) Strong royalty portfolio; stable revenue stream; financially sound Oncology focus; early-stage pipeline; strong cash position[](https://investorshub.advfn.com/Biotech-Values-1418) Al-driven platform; early-stage pipeline; moderate cash runway Imcivree commercial success; expanding pipeline; stable finances Rare disease focus; early-stage pipeline; moderate cash runway[](https://www.biopharmcatalyst.com/news/2024/rezolute-rzlt-phase-2-data-pliant-plrx-preclinical-data) Zurzuvae commercializing; CNS focus; Biogen partnership key Cell therapy focus; early-stage pipeline; stable cash position High-risk gene therapy; limited cash runway; Pfizer partnership Gene therapy focus; early-stage pipeline; moderate cash runway DCCR nearing approval; rare disease focus; strong cash position[](https://finance.yahoo.com/quote/SLNO/) Oncology focus; ivonescimab promising; Akeso partnership Neffy recently approved; commercial ramp-up critical; stable finances CNS focus; STK-001 promising; stable cash position Immunology focus; early-stage pipeline; moderate cash runway Cell therapy focus; early-stage pipeline; moderate cash runway[](https://www.benzinga.com/general/biotech/21/09/22947673/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-cal Briumvi strong commercial traction; expanding indications; financially stable High-risk oncology; limited cash runway; early-stage pipeline Oncology focus; early-stage pipeline; moderate cash runway Immunology focus; TOUR006 promising; stable cash position VK2735 promising in obesity; strong cash position; high market interest Immunology focus; VRDN-001 pivotal data key; moderate cash runway Ohtuvayre recently approved; commercial ramp-up critical; stable finances Oncology focus; early-stage pipeline; moderate cash runway Neuro focus; early-stage pipeline; Neurocrine partnership Rare disease focus; WVE-006 promising; GSK partnership Azatirionant pivotal data key; CNS focus; strong cash position[](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/estimating-the-intrinsic-value-of-xenon-pharmaceuticals-ir Multiple commercial products; stable revenue; niche endocrinology market Oncology focus; FDA lifted clinical hold on azenosertib; moderate cash runway[](https://finance.yahoo.com/news/biotech-stock-roundup-gild-nuvl-132100903.html?.tsrc=rss) High-risk oncology; limited cash runway; early-stage pipeline Royalty-based model; stable revenue; Q1 2025 revenue beat expectations [](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xoma/xoma-royalty/news/xoma-royalty-first-quarter-2025-earnings-beats-expectal Azstarys commercialized; niche CNS market; stable finances Immunology focus; obexelimab promising; phase 3 data expected soon[](https://seekingalpha.com/article/4773527-zenas-differentiated-b-cell-targeting-drug-with-q3-of-2025-catalyst)

Oncology focus; zanidatamab pivotal data key; strong partnerships